[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 8939
1. Ren HZ, Wang JS, Wang P, Pan GQ, Wen JF, Fu H, Shan XZ: Increased expression of prohibitin and its relationship with poor prognosis in esophageal squamous cell carcinoma. Pathol Oncol Res; 2010 Dec;16(4):515-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prohibitin, a potential tumor suppressor, has been shown to be an anti- proliferative protein, a regulator of cell-cycle progression and in apoptosis.
  • Recently, it was found to be over-expressed in breast cancer and gastric cancer, and it has been suggested as a biomarker in those diseases.
  • The over-expression of prihibitin was significantly correlated with the depth of tumor, lymph node metastasis, distant metastasis, lymphatic invasion and vascular invasion of ESCC.
  • These results suggested that prohibitin(+), lymph node metastasis and distant metastasis could be the independent risk factors for worse prognosis in ESCC patients.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2009 May;40(5):714-25 [19121846.001]
  • [Cites] J Gastroenterol. 2008;43(8):618-25 [18709484.001]
  • [Cites] Ann Thorac Surg. 2003 Oct;76(4):S1367-9 [14530066.001]
  • [Cites] Cell Growth Differ. 1996 Jul;7(7):871-8 [8809404.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Exp Gerontol. 1995 Mar-Apr;30(2):99-124 [8591812.001]
  • [Cites] FEBS Lett. 1995 Jan 30;358(3):273-7 [7843414.001]
  • [Cites] Exp Gerontol. 1996 Jan-Apr;31(1-2):245-52 [8706794.001]
  • [Cites] Oncogene. 1999 Jun 10;18(23):3501-10 [10376528.001]
  • [Cites] EMBO J. 2000 Jun 1;19(11):2444-51 [10835343.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cancer Lett. 2008 Aug 8;266(2):171-85 [18384941.001]
  • [Cites] Exp Cell Res. 1996 Apr 10;224(1):128-35 [8612677.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1737-46 [11698334.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):201-7 [8062216.001]
  • [Cites] Mech Ageing Dev. 2002 Feb;123(4):287-95 [11744041.001]
  • [Cites] Surg Oncol. 1997 Dec;6(4):193-200 [9775405.001]
  • [Cites] Exp Cell Res. 2001 May 1;265(2):262-73 [11302691.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2179-83 [15259061.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):1981-2 [11130529.001]
  • (PMID = 20069396.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / prohibitin
  •  go-up   go-down


2. Zhang JP, Lu WG, Ye F, Chen HZ, Zhou CY, Xie X: Study on CXCR4/SDF-1alpha axis in lymph node metastasis of cervical squamous cell carcinoma. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study on CXCR4/SDF-1alpha axis in lymph node metastasis of cervical squamous cell carcinoma.
  • CXCR4/stromal-cell-derived factor-1alpha (SDF-1alpha) is involved in many cancer metastatic mechanisms.
  • Cervical squamous cell cancer (SCC) tissues (n=35), normal cervical tissues (n=10), metastatic (n=10) and nonmetastatic lymph nodes (n=50), and Hela cells were stained immunohistochemically with CXCR4 monoclonal antibody (mAb).
  • Meanwhile, lymph nodes were stained immunohistochemically with rabbit anti-SDF-1alpha.
  • For evaluating the effect of CXCR4/SDF-1alpha on proliferation of cervical cancer cells, Hela cells were cultured for 72 h exposed to SDF-1alpha with and without CXCR4 mAb.
  • We found that CXCR4 was expressed on SCC cells in all cervical cancer, metastatic lymph node, and Hela cells but not in normal cervix.
  • SDF-1alpha was expressed on lymph cells in all lymph nodes.
  • CXCR4/SDF-1alpha axis probably participates in the metastasis toward lymph nodes in cervical cancer.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / pharmacology. Cell Movement / drug effects. Cell Proliferation / drug effects. Chemokine CXCL12. Female. HeLa Cells. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Middle Aged


3. Baek SJ, Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH: Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol; 2008 Dec;19(4):223-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer.
  • OBJECTIVE: To verify whether it can be justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only.
  • METHODS: This study included all consecutive patients with stage IIIC epithelial ovarian cancer who underwent upfront cytoreductive surgery according to the FIGO guideline followed by platinum based chemotherapy from September 1989 to September 2006 at Asan Medical Center.
  • RESULTS: During the study period, a total of 272 patients met the inclusion criteria.
  • Forty-one patients were allocated to stage IIIC by positive nodes only.
  • Patients with stage IIIC disease due to positive nodes only had significantly longer DFS and OS compared to other stage IIIC patients (p<0.001 and p<0.001).
  • CONCLUSION: Patients with stage IIIC epithelial ovarian cancer due to positive nodes only had a more favorable prognosis compared to other stage IIIC patients.
  • Therefore, reevaluation of the current FIGO staging system for stage IIIC epithelial ovarian cancer is required.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):154-6 [17614126.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):781-2 [17141679.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):797-801 [17052746.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):237-41 [10329040.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1555-60 [9781949.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):467-72 [9190977.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):345-52 [7705667.001]
  • [Cites] Gynecol Oncol. 1994 Oct;55(1):108-10 [7959250.001]
  • [Cites] Am J Obstet Gynecol. 1994 Feb;170(2):656-62 [8116728.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):150-4 [8276287.001]
  • [Cites] Gynecol Oncol. 1991 Feb;40(2):103-6 [2010101.001]
  • [Cites] Eur J Gynaecol Oncol. 1988;9(1):36-9 [3345782.001]
  • [Cites] Gynecol Oncol. 1987 Jul;27(3):368-72 [3623232.001]
  • [Cites] Cancer. 1985 May 1;55(9):2019-25 [3978582.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Am J Obstet Gynecol. 1974 Aug 15;119(8):1013-7 [4847438.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1161-3 [11870155.001]
  • (PMID = 19471577.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676474
  • [Keywords] NOTNLM ; Epithelial ovarian cancer / Lymph node metastasis / Prognosis / Stage IIIC
  •  go-up   go-down


Advertisement
4. Nomura H, Uzawa K, Yamano Y, Fushimi K, Ishigami T, Kouzu Y, Koike H, Siiba M, Bukawa H, Yokoe H, Kubosawa H, Tanzawa H: Overexpression and altered subcellular localization of autophagy-related 16-like 1 in human oral squamous-cell carcinoma: correlation with lymphovascular invasion and lymph-node metastasis. Hum Pathol; 2009 Jan;40(1):83-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression and altered subcellular localization of autophagy-related 16-like 1 in human oral squamous-cell carcinoma: correlation with lymphovascular invasion and lymph-node metastasis.
  • Autophagy is a dynamic process of subcellular degradation, which has recently sparked great interest because it is involved in various developmental processes and various diseases including cancer.
  • Autophagy-related 16-like 1 is a component of a large protein complex essential for autophagosome formation.
  • Autophagy-related 16-like 1 immunoreaction was predominant in a variety of subcellular components of oral squamous cell carcinoma tissues, including the cytoplasm and plasma membrane of malignant cells (45% and 39%, respectively) and peritumoral and intratumoral stroma (52%), whereas all of the components in normal tissues had no or faint autophagy-related 16-like 1 expression.
  • In addition, high stromal expression of autophagy-related 16-like 1 was associated significantly with lymphovascular invasion of tumor cells (P = .037) and positive lymph node status (P = .015).
  • Our finding suggests that dysregulation of autophagy-related 16-like 1 protein expression is a frequent and early event during oral carcinogenesis and could affect the malignant behavior of oral squamous cell carcinoma cells.
  • [MeSH-major] Autophagy. Carcinoma, Squamous Cell / metabolism. Lymph Nodes / metabolism. Mouth Neoplasms / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Membrane / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged


5. Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z, Sun YM, Sun LC, Pan J, Sun LX, Zhao P, Yang ZH: Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis; 2009 Oct;30(10):1660-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway.
  • The purpose of this study was to investigate invasion- and metastasis-related genes in gastric cancer.
  • Immunohistochemical analysis revealed that LOXL2 expression was markedly increased in carcinoma relative to normal epithelia, and this overexpression in primary tumor was significantly associated with depth of tumor invasion, lymph node metastasis and poorer overall survival.
  • Moreover, LOXL2 expression was further increased in lymph node metastases compared with primary cancer tissues.
  • RNA interference-mediated knockdown and ectopic expression of LOXL2 showed that LOXL2 promoted tumor cell invasion in vitro and increased gastric carcinoma metastasis in vivo.
  • However, secreted LOXL2 induced gastric tumor cell invasion and metastasis exclusively via the Src/FAK pathway.
  • We then evaluated secreted LOXL2 as a target for gastric carcinoma treatment and found that an antibody against LOXL2 significantly inhibited tumor growth and metastasis.
  • Overall, our data revealed that LOXL2 overexpression, a frequent event in gastric carcinoma progression, contributes to tumor cell invasion and metastasis, and LOXL2 may be a therapeutic target for preventing and treating metastases.
  • [MeSH-minor] Animals. Cell Adhesion. Cell Line, Tumor. Cloning, Molecular. DNA Primers. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Inverted Repeat Sequences / genetics. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Metastasis / pathology. Transfection. src-Family Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19625348.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.- / LOXL2 protein, human; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


6. Lan L, Sun T, Liu D, Pang J, Yang L, Yang C, Xiong D: [Expression of ezrin in human lung carcinoma and its clinicopathologic significance.]. Zhongguo Fei Ai Za Zhi; 2008 Feb 20;11(1):67-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metastasis is the main cause of cancer related mortality, and identification of genes involved in tumor metastasis is important for effective therapies.
  • The membrane cytoskeletal crosslinker participated in several functions including cell adhersion, motility and cell survival, and there is increasing evidence that it regulates tumor progression.
  • However, the role played by ezrin in lung cancer metastasis has not been clearly delineated.
  • METHODS: Ezrin expression was detected by two- step immunohistochemical staining technique in tumor tissues from 75 lung cancer cases and in normal lung tissues from 16 cases with benign disease and analyzed by the lung cancer clinicopathologic characteristics.
  • The gene and protein level expression of Ezrin in lung cancer cell lines was also detected by Confocal Laser Scanning Microscope (CLSM) and RT-PCR.
  • RESULTS: The positive incidence of ezrin expression (77.3%) was significantly lower in lung cancer tissues than that in normal tissues (100%) (P<0.05), and the down-regulated of ezrin expression was significantly correlated with lymph node metastasis and distant metastasis (P<0.05) and was not correlated with gender, age, tumor size, pathological type, the degree of differentiation of tissue and clinical stage.
  • Otherwise, the subcellular redistribution of ezrin from cell membrane to cell plasma was significantly correlated with lymph node metastasis (P< 0.05), in consistance with in vitro experimental result.
  • High metastasis cell line BE1 had the lowest expression of ezrin under CLSM, similar to RT-PCR, and ezrin was mainly located in cell plasma under CLSM.
  • CONCLUSIONS: Ezrin expression is down-regulated in lung cancer tissue and lung cancer cell line, and the locational change from cell membrane to cell plasma may be associated with the oncogenesis and development of lung cancer.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20727270.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Park HS, Lee JM, Choi JY, Lee MW, Kim HJ, Han JK, Choi BI: Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am J Roentgenol; 2008 Feb;190(2):396-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography.
  • OBJECTIVE: The purpose of this study was to compare the performance of MRI combined with MR cholangiopancreatography (MRCP) with that of MDCT combined with direct cholangiography in the evaluation of the tumor extent and resectability of bile duct cancer with surgical and pathologic findings as the reference standard.
  • MATERIALS AND METHODS: From January 2003 to March 2006, 27 patients (18 men, nine women; mean age, 60.8 years; range, 43-80 years) with surgically proven hilar cholangiocarcinoma or common bile duct (CBD) cancer who had undergone preoperative 2D and 3D MRCP with gadolinium-enhanced MRI and triple-phase MDCT with direct cholangiography (ERCP or percutaneous transhepatic cholangiography) were included in this retrospective study.
  • These readers evaluated the longitudinal extent of the tumor for involvement of the secondary confluence of both intrahepatic ducts and the intrapancreatic CBD, vascular involvement of the tumor, lymph node metastasis, and tumor resectability.
  • RESULTS: For each reviewer, the overall accuracy rates for predicting involvement of the bilateral secondary biliary confluences and the intrapancreatic CBD were 90.7% and 87.0% for MRI with MRCP and 85.1% and 87.0% for MDCT with direct cholangiography.
  • In the assessment of vascular involvement, lymph node metastasis, and tumor resectability, the readers' diagnostic performance using MRI with MRCP was similar to that with MDCT with direct cholangiography (p > 0.05).
  • CONCLUSION: In the diagnosis of bile duct cancer with a noninvasive procedure, the information regarding tumor extent and resectability obtained with contrast-enhanced MRI combined with MRCP is comparable with that obtained with MDCT with direct cholangiography.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Cholangiography / methods. Cholangiopancreatography, Magnetic Resonance / methods. Preoperative Care / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212225.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Hidaka H, Eto T, Maehara N, Jimi S, Hotokezaka M, Chijiiwa K: Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer. Hepatogastroenterology; 2008 Nov-Dec;55(88):2269-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer.
  • BACKGROUND/AIMS: Lymph node metastasis (pN) is one of the most significant prognostic factors in patients with gastric cancer.
  • The pN classification of the Japanese Gastric Cancer Association (JGCA) is based on the anatomical site of metastatic nodes from the primary tumor, whereas that of the International Union Against Cancer (UICC) is based on the number of nodes involved.
  • METHODOLOGY: From 1992 to 2002, a total of 318 patients at our hospital underwent surgical resection with lymph node dissection for primary gastric cancer.
  • CONCLUSIONS: The better differentiation of outcomes by the UICC-pN system suggests that the number of metastatic lymph nodes is more important than the anatomical site in predicting outcomes.
  • [MeSH-major] Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260520.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


9. Zheng X, Zhao Y, Wang X, Li Y, Wang R, Jiang Y, Gong T, Li M, Sun L, Hong L, Li X, Liang J, Luo G, Jin B, Yang J, Zhang H, Fan D: Decreased expression of CIAPIN1 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Dig Dis Sci; 2010 Dec;55(12):3408-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We found that the expression of CIAPIN1 was statistically correlated with the degree of differentiation, depth of invasion, and lymph node metastasis of ESCC.
  • However, no significant difference was observed between CIAPIN1 expression and the patient age, sex, tumor location, and distant metastasis.
  • Furthermore, multivariate analysis was performed by using Cox's proportional hazards model, and the results showed that lymph node metastases and CIAPIN1 expression were two independent prognostic factors.
  • Finally, functional enhancement of CIAPIN1 might lead to a novel strategy for the treatment of SCC in the esophagus.
  • [MeSH-minor] Aged. Cell Differentiation. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. Proportional Hazards Models

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3237-42 [16718845.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):197-202 [12894012.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2003 Feb;9(1):6-13 [12667124.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):946-54 [10964323.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] J Histochem Cytochem. 2006 Apr;54(4):417-26 [16314443.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):832-41 [11937319.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):94-101 [16051426.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1434-43 [12237911.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1856-62 [7728753.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1740-8 [15980157.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1393-400 [12883713.001]
  • [Cites] J Exp Med. 2004 Feb 16;199(4):581-92 [14970183.001]
  • [Cites] J Gastrointest Surg. 2010 Feb;14 Suppl 1:S75-80 [19756878.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3977-84 [12553021.001]
  • [Cites] Cancer. 2002 May 1;94(9):2511-6 [12015777.001]
  • [Cites] J Histochem Cytochem. 2006 Dec;54(12):1437-44 [16957168.001]
  • [Cites] Cancer Biol Ther. 2007 Oct;6(10):1539-45 [18293492.001]
  • [Cites] Hybridoma (Larchmt). 2005 Jun;24(3):141-5 [15943561.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):257-61 [16299785.001]
  • [Cites] Surg Clin North Am. 2002 Aug;82(4):729-46 [12472127.001]
  • [Cites] Hematology. 2005;10 Suppl 1:73-5 [16188641.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):225-32 [10903602.001]
  • [Cites] Mol Biol (Mosk). 2008 Jan-Feb;42(1):102-9 [18389626.001]
  • (PMID = 20411424.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CIAPIN1 protein, human; 0 / Intracellular Signaling Peptides and Proteins
  •  go-up   go-down


10. Ito Y, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A: Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology; 2005;68(2-3):87-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination.
  • OBJECTIVES: We recently demonstrated that papillary microcarcinomas with preoperatively detectable node metastasis in the lateral compartment on ultrasonography (clinically apparent metastasis) show worse postoperative relapse-free survival than those with no metastasis or metastasis that could not be detected preoperatively, but was confirmed by pathological examination after surgery (occult metastasis).
  • MATERIALS AND METHODS: We immunohistochemically examined the expression of cell proliferating markers, Ki-67, cyclin D1, p27, and retinoblastoma gene product (pRb), apoptotic markers, single-strand DNA (ssDNA), and metastatic suppressor, kangai-1 (KAI-1) for 19 microcarcinoma patients with clinically apparent metastasis, 14 patents with occult metastasis, and 22 patients without metastasis.
  • RESULTS: Cases of clinically apparent metastasis showed increased cyclin D1 expression together with decreased p27 expression and higher levels of pRb and Ki-67 expression.
  • There was no significant difference in the expression of these proteins between cases demonstrating no and occult metastases.
  • CONCLUSION: These findings suggest that cases of clinically apparent metastasis show significantly higher growth based on cell proliferating activity, apoptosis, and expression of metastatic suppressor than those demonstrating no or occult metastases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / pathology. Lymph Nodes / pathology. Thyroid Neoplasms / chemistry. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. Antigens, CD82. Apoptosis. Cell Cycle Proteins / analysis. Cyclin D1 / analysis. Cyclin-Dependent Kinase Inhibitor p27. DNA, Single-Stranded / analysis. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Lymphatic Metastasis / ultrasonography. Male. Membrane Glycoproteins / analysis. Middle Aged. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Retinoblastoma Protein / analysis. Treatment Outcome. Tumor Suppressor Proteins / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15886500.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD82; 0 / Biomarkers, Tumor; 0 / CD82 protein, human; 0 / Cell Cycle Proteins; 0 / DNA, Single-Stranded; 0 / Ki-67 Antigen; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


11. Nakayama T, Noguchi S: Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. Oncologist; 2010;15(1):26-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
  • In Japan, the history of postoperative chemotherapy for breast cancer started with 5-fluorouracil (5-FU), launched in the 1980s.
  • Currently, oral fluoropyrimidine-based regimens indicated for the treatment of breast cancer in Japan include tegafur plus uracil (UFT); tegafur, gimeracil, and oteracil (TS-1); doxifluridine; and capecitabine.
  • Recent studies have shown that UFT prolongs survival after tumor resection in patients with gastric cancer, colorectal cancer, and lung cancer.
  • In patients with breast cancer, large clinical trials of UFT-based postoperative chemotherapy conducted in Japan have shown that UFT is useful for the treatment of intermediate-risk patients with no lymph node metastasis.
  • The types of patients most likely to benefit from UFT are discussed on the basis of currently available evidence and a global consensus of treatment recommendations.
  • The optimal timing of endocrine therapy and strategies for postoperative adjuvant chemotherapy with UFT in patients with breast cancer are also discussed.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gan. 1980 Feb;71(1):112-23 [6445847.001]
  • [Cites] Nihon Gan Chiryo Gakkai Shi. 1990 Dec 20;25(12):2767-73 [2074386.001]
  • [Cites] Gan. 1977 Oct;68(5):553-60 [22472.001]
  • [Cites] Gan. 1979 Apr;70(2):209-14 [381088.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2185-91 [10473104.001]
  • [Cites] Nature. 1957 Mar 30;179(4561):663-6 [13418758.001]
  • [Cites] Cancer Res. 1958 Apr;18(3):318-28 [13523598.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2172-84 [15800310.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8331-9 [16293864.001]
  • [Cites] JAMA. 2006 Apr 12;295(14):1658-67 [16609087.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):237-44 [16675478.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3623-8 [16877730.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Oct;33(10):1423-9 [17033231.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):515-25 [16900372.001]
  • [Cites] Oncol Rep. 2007 Aug;18(2):313-9 [17611650.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1133-44 [17675394.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1477-83 [17515403.001]
  • [Cites] Int J Oncol. 2007 Oct;31(4):899-906 [17786323.001]
  • [Cites] N Engl J Med. 2007 Oct 11;357(15):1496-506 [17928597.001]
  • [Cites] Br J Surg. 2007 Dec;94(12):1468-76 [17948223.001]
  • [Cites] Breast Cancer Res Treat. 2008 Aug;110(3):531-9 [17879158.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1368-74 [19204202.001]
  • [Cites] N Engl J Med. 2009 May 14;360(20):2055-65 [19439741.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):598-604 [19638976.001]
  • [Cites] Gan To Kagaku Ryoho. 2009 Sep;36(9):1465-74 [19755814.001]
  • [Cites] Lancet. 2009 Dec 19;374(9707):2055-63 [20004966.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(2):113-24 [10573104.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4409-15 [11106261.001]
  • [Cites] Int J Oncol. 2002 Mar;20(3):517-25 [11836563.001]
  • [Cites] Angiogenesis. 2001;4(3):163-73 [11911014.001]
  • [Cites] Oncology. 2003;64(2):146-53 [12566912.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • [Cites] Anticancer Drugs. 2004 Jan;15(1):55-61 [15090744.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Dokl Akad Nauk SSSR. 1967 Sep 11;176(2):332-5 [5623427.001]
  • (PMID = 20080863.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 039LU44I5M / Floxuridine; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine; YL5FZ2Y5U1 / Methotrexate; CMF protocol
  • [Number-of-references] 46
  • [Other-IDs] NLM/ PMC3227888
  •  go-up   go-down


12. Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE: Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery; 2009 Dec;146(6):1215-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To date, a mutation of the BRAF oncogene is the most common genetic alteration found in papillary thyroid carcinoma (PTC) and is associated with extrathyroidal extension, lymph node metastasis, and tumor recurrence.
  • Pre-operative cytologic identification of BRAF mutation has high specificity and may guide the initial extent of thyroidectomy and node dissection.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Substitution. Cohort Studies. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / surgery. Reoperation. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958951.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


13. Yu H, Zhang S, Zhang R, Zhang L: The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma. J Exp Clin Cancer Res; 2009;28:98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma.
  • BACKGROUND: To investigate the role of vascular endothelial growth factors (VEGF)-C/D and their receptor Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma.
  • (1) The positive rates of VEGF-C, VEGF-D, and Flt-4 were 57.7%, 60.8%, and 52.6% in the cervical tumor samples, respectively. (2) The expression levels of VEGF-C, VEGF-D, and Flt-4 were significantly correlated with lymphatic metastasis and lymphatic vessel invasion.
  • LVD was significantly associated with lymph node metastasis and lymphatic vessel invasion.
  • CONCLUSION: VEGF-C/D and Flt-4 may play an important role in the process of lymphatic metastasis of early-stage invasive cervical carcinoma through paracrine and autocrine mechanisms.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Uterine Cervical Neoplasms / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor D / metabolism. Vascular Endothelial Growth Factor Receptor-3 / metabolism
  • [MeSH-minor] Endothelium, Lymphatic / metabolism. Endothelium, Lymphatic / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Vesicular Transport Proteins

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2005 Sep;27(3):669-79 [16077915.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1127-33 [15803188.001]
  • [Cites] J Cell Physiol. 2006 Apr;207(1):107-13 [16261591.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):209-23 [16530705.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):691-6 [16793912.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1090-8 [17912247.001]
  • [Cites] Pathol Int. 2008 Oct;58(10):611-9 [18801080.001]
  • [Cites] Oncol Rep. 2008 Oct;20(4):721-5 [18813809.001]
  • [Cites] BMC Cancer. 2009;9:64 [19232130.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5598-605 [11114740.001]
  • [Cites] Mol Cell. 2000 Oct;6(4):851-60 [11090623.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):713-22 [12566318.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3361-70 [12776187.001]
  • [Cites] Head Neck. 2003 Jun;25(6):464-74 [12784238.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):413-23 [12872364.001]
  • [Cites] J Pathol. 2003 Dec;201(4):544-54 [14648657.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Science. 1997 May 30;276(5317):1423-5 [9162011.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):228-40 [16344322.001]
  • (PMID = 19589137.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LYVE1 protein, human; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D; 0 / Vesicular Transport Proteins; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  • [Other-IDs] NLM/ PMC2714300
  •  go-up   go-down


14. Choi MG, Sohn TS, Park SB, Paik YH, Noh JH, Kim KM, Park CK, Kim S: Decreased expression of p12 is associated with more advanced tumor invasion in human gastric cancer tissues. Eur Surg Res; 2009;42(4):223-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of p12 is associated with more advanced tumor invasion in human gastric cancer tissues.
  • We investigated the expression of p12(DOC-1) in gastric cancer tissues and its possible correlation with p53 expression, and determined its clinical significance.
  • The negative expression of p12(DOC-1) was significantly associated with a more advanced depth of tumor invasion and stage (p < 0.05).
  • Multivariate analysis revealed that lymph node metastasis, distant metastasis, lymphatic invasion and perineural invasion were independent prognostic factors.
  • CONCLUSIONS: This is the first report that suggests that p12(DOC-1) may be involved in the development and progression of gastric cancer.
  • [MeSH-major] Carcinoma / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Stomach / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19279387.001).
  • [ISSN] 1421-9921
  • [Journal-full-title] European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes
  • [ISO-abbreviation] Eur Surg Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CDK2AP1 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


15. Wallin AR, Svanvik J, Adell G, Sun XF: Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy. Int J Radiat Oncol Biol Phys; 2006 Jun 1;65(2):452-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: PRL-3 (phosphatase of regenerating liver) is involved in metastasis of colorectal cancer; however, its therapeutic implication in cancer patients has not been studied.
  • We investigated the relationships of PRL expression to radiotherapy (RT) in rectal cancer patients.
  • METHODS AND MATERIALS: Phosphatase of regenerating liver expression was immunohistochemically examined in distant (n = 36) and adjacent (n = 82) normal mucosa, primary tumor (n = 125), biopsy specimens (n = 96), and lymph node metastasis (n = 30) from rectal cancer patients participating in a clinical trial of preoperative RT.
  • RESULTS: Phosphatase of regenerating liver expression was increased from the distant to adjacent mucosa and to the primary tumor (p < 0.05).
  • PRL was highly expressed at the invasive margin in 28% of the primary tumors and 26% of the metastases.
  • In the RT group, strong PRL expression at the invasive margin was related to distant recurrence (p = 0.006) and poor survival (p = 0.01), but not in the non-RT group.
  • Additional multivariate analyses showed that the correlation with prognostic significance of PRL differed between the RT and non-RT groups (p = 0.01).
  • CONCLUSION: Phosphatase of regenerating liver expression (rather than PRL-3 alone) at the invasive margin predicted resistance to RT and unfavorable survival in rectal cancer patients with preoperative RT.
  • [MeSH-major] Intestinal Mucosa / enzymology. Neoplasm Proteins / analysis. Protein Tyrosine Phosphatases / analysis. Rectal Neoplasms / enzymology. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Rectum / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626893.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


16. Choi BJ, Kim CJ, Cho YG, Song JH, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY, Park WS: Altered expression of CDX2 in colorectal cancers. APMIS; 2006 Jan;114(1):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Statistically, CDX2 protein expression was related to tumor stage (Bartholomew test, p<0.05) and lymph node metastasis (Chi-Square test, p<0.05).
  • [MeSH-major] Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / diagnosis. Homeodomain Proteins / analysis. Homeodomain Proteins / metabolism
  • [MeSH-minor] Disease Progression. Down-Regulation. Humans. Immunohistochemistry. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499661.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


17. Endo K, Kohnoe S, Tsujita E, Watanabe A, Nakashima H, Baba H, Maehara Y: Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res; 2005 Jul-Aug;25(4):3117-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 expression is a potent prognostic marker in colorectal cancer.
  • BACKGROUND: Galectin-3 is a beta-galactoside-binding protein whose expression has been correlated with progression and metastasis in colon cancer.
  • It is expressed at elevated levels in a variety of neoplastic cells.
  • The current study was designed to investigate, by clinicopathological analysis, the relationship between prognosis and galectin-3 expression, in colorectal cancer.
  • PATIENTS AND METHODS: Galectin-3 expression was evaluated using immunohistochemical staining in 121 consecutive patients with colorectal cancer.
  • The incidence of lymph node and distant metastasis in galectin 3-positive cancer was significantly higher than that in galectin-3-negative cases (p = 0.0007 and p = 0.014, respectively).
  • While univariate analysis showed that survival in patients with galectin-3-positive expression was significantly poorer than in galectin-3-negative cases (p = 0.0027), galectin-3 expression was a prognostic factor independent of Dukes' stage and lymph node metastasis by multivariate analysis.
  • CONCLUSION: We propose that galectin-3 expression is an independent factor for prognosis in colorectal cancer.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / metabolism. Galectin 3 / biosynthesis
  • [MeSH-minor] Aged. Cytoplasm / metabolism. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging


18. Hamai Y, Matsumura S, Matsusaki K, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Toge T, Yasui W: A single nucleotide polymorphism in the 5' untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology; 2005;72(3):133-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single nucleotide polymorphism in the 5' untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer.
  • OBJECTIVE: Epidermal growth factor (EGF) has many biological functions and plays an important role in the progression of various tumors including gastric cancer.
  • We examined whether this polymorphism is correlated with the development and malignant phenotypes of gastric cancer.
  • METHODS: The study population included 200 gastric cancer patients and 230 healthy control subjects.
  • RESULTS: The A allele was significantly less frequent in patients than in controls (p = 0.01).
  • Individuals with the A/A or A/G genotype showed a significantly lower risk of gastric cancer than those with the G/G genotype [adjusted odds ratio (OR) = 0.56], whereas the same genotypes were associated with malignant progression of this cancer, e.g. deeper tumor invasion, increased lymph node metastasis and advanced clinical stage, and histological classification in gastric cancer patients (adjusted OR = 1.80, 1.98, 2.26 and 1.89, respectively).
  • CONCLUSIONS: Our findings suggest that the A-G polymorphism of EGF is involved not only in the occurrence but also in the malignant progression of gastric cancer.
  • [MeSH-minor] Adult. Aged. Alleles. DNA, Neoplasm / genetics. Disease Progression. Female. Gene Frequency. Genotype. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15860930.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


19. Lo CK, Yu CH, Ma CC, Ko KM, Leung SC: Surgical management of primary non-small-cell carcinoma of lung with synchronous solitary brain metastasis: local experience. Hong Kong Med J; 2010 Jun;16(3):186-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of primary non-small-cell carcinoma of lung with synchronous solitary brain metastasis: local experience.
  • OBJECTIVE: To report the surgical experience in the management of patients with synchronous primary lung cancer and solitary brain metastasis.
  • PATIENTS: Seventeen patients with synchronous primary lung cancer and solitary brain metastasis were treated by pulmonary resection and neurosurgical intervention between 1994 and 2007.
  • Four out of six patients who had lymph node metastases developed tumour recurrence.
  • CONCLUSION: In view of encouraging survival results, aggressive therapy including pulmonary resection and neurosurgical intervention should be recommended for patients with synchronous presentation with primary lung cancer and solitary brain metastasis.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519754.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Murphy S, Hayes AM, Blackwood L, Maglennon G, Pattinson H, Sparkes AH: Oral malignant melanoma - the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol; 2005 Dec;3(4):222-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral malignant melanoma - the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy.
  • Abstract A retrospective study was undertaken of dogs presented to the Animal Health Trust for treatment of oral malignant melanoma, without radiographic evidence of pulmonary metastases.
  • Group 1 (n = 13) received radiotherapy of the primary and any lymph node metastases (4 weekly fractions of 9 Gy); and group 2 (n = 15) were treated the same but additionally received between two and six doses carboplatin at 300 mg m(-2) every 3 weeks.
  • In addition, carboplatin therapy did not significantly reduce the proportion of dogs dying due to metastases (three from group 1 and four from group 2).
  • We found no evidence of a beneficial effect of carboplatin therapy over radiotherapy alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754777.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Boland PW, Watt-Smith SR, Pataridis K, Alvey C, Golding SJ: Evaluating lingual carcinoma for surgical management: what does volumetric measurement with MRI offer? Br J Radiol; 2010 Nov;83(995):927-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Measurement of three-dimensional tumour volume (TV) has the potential to guide management of clinically negative cervical lymph nodes and address deficiencies in current TNM staging criteria This work studied the value of MRI-measured TV as a predictor of 2 year disease-related survival (DRS) and disease-free survival (DFS), as well as occult cervical lymph node metastasis (OM) in lingual cancer.
  • Similarly, a significant relationship between TV and occult cervical lymph node metastasis was discovered using a 3 cm³ cut-off (OR = 6.7, p = 0.02, Fisher's Exact Test).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Magnetic Resonance Imaging / methods. Mouth Neoplasms / pathology. Tumor Burden
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck. Neck Dissection / methods. Neoplasm Staging. Prognosis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):699-702 [8018319.001]
  • [Cites] Head Neck. 1991 Jul-Aug;13(4):277-81 [1869430.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):373-80 [7526718.001]
  • [Cites] Laryngoscope. 1997 Sep;107(9):1239-44 [9292610.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):535-9 [9486601.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1443-8 [9554518.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Oct;26(9):2384-9 [16219850.001]
  • [Cites] Head Neck. 2005 Dec;27(12):1080-91 [16240329.001]
  • [Cites] Eur Radiol. 2006 Oct;16(10):2242-8 [16636800.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):58-66 [16829010.001]
  • [Cites] Head Neck. 2007 Feb;29(2):104-8 [17111434.001]
  • [Cites] Acta Oncol. 2007;46(3):386-94 [17450476.001]
  • [Cites] ANZ J Surg. 2007 Aug;77(8):632-7 [17635274.001]
  • [Cites] BMJ. 2000 Jul 8;321(7253):97-100 [10884263.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):139-43 [11044531.001]
  • [Cites] Laryngoscope. 2002 Mar;112(3):457-61 [12148854.001]
  • [Cites] Strahlenther Onkol. 2003 May;179(5):292-7 [12740655.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):59-66 [15093899.001]
  • [Cites] Radiology. 2004 Jun;231(3):914-21 [15163826.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Jun-Jul;25(6):1092-8 [15205156.001]
  • [Cites] Laryngoscope. 1972 Jul;82(7):1273-81 [5078645.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1983 Jun;8(3):197-203 [6883783.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):158-62 [3708540.001]
  • [Cites] Arch Surg. 1986 Dec;121(12):1410-4 [3789911.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1987 Sep-Oct;96(5):514-8 [3674647.001]
  • [Cites] Rofo. 1989 Apr;150(4):425-33 [2539621.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1195-202 [2766218.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):405-9 [2221244.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):717-20 [8018323.001]
  • (PMID = 20965903.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3473734
  •  go-up   go-down


22. Ohtani H, Arimoto Y, Nishio K, Adachi K, Ohba H, Shintani M, Yui S: [A case of advanced gastric cancer with pulmonary carcinomatous lymphangitis and paraaortic lymph node metastases responding to combination chemotherapy of S-1 and irinotecan(CPT-11)]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1563-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with pulmonary carcinomatous lymphangitis and paraaortic lymph node metastases responding to combination chemotherapy of S-1 and irinotecan(CPT-11)].
  • A 70-year-old woman with pulmonary carcinomatous lymphangitis and paraaortic lymph node metastases due to gastric cancer, was treated by combination chemotherapy of S-1 and irinotecan (CPT-11).
  • After one course of the chemotherapy, pulmonary carcinomatous lymphangitis and paraaortic lymph node metastases were remarkably improved.
  • Diet intake was improving and cancer pain remarkably declined.
  • Because the origin of gastric cancer was not improved, total gastrectomy, distal pancreatectomy and splenectomy were performed.
  • The combination chemotherapy of S-1 and CPT-11 was effective for pulmonary carcinomatous lymphangitis and paraaortic lymph nodes metastases due to gastric cancer.
  • [MeSH-minor] Aged. Drug Combinations. Female. Gastroscopy. Humans. Lymphatic Metastasis / radiography. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Failure

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799912.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


23. Park JS, Son KR, Na DG, Kim E, Kim S: Performance of preoperative sonographic staging of papillary thyroid carcinoma based on the sixth edition of the AJCC/UICC TNM classification system. AJR Am J Roentgenol; 2009 Jan;192(1):66-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two experienced radiologists prospectively evaluated primary tumors (e.g., diameter, number, presence of extrathyroidal invasion) and cervical lymph nodes for metastasis.
  • Lymph nodes were divided into central and lateral groups according to N staging requirements.
  • The sonographic criteria for lymph node metastasis were an absent hilum, hyperechoic change, a round shape, calcification, cystic change, or an abnormal color Doppler pattern.
  • Sonography accurately identified 75.9% (22/29) of patients with multifocal cancer and 83.3% (15/18) of patients with bilateral cancers.
  • Using a cutoff value of 50% or more of the tumor abutting the thyroid capsule (grade 2), the sensitivity, specificity, and accuracy of sonography in predicting extrathyroidal invasion were 85.3%, 70.0%, and 74.5%, respectively, and the overall accuracy of sonography for T staging was 67.0% (63/94).
  • One hundred forty-seven cervical lymph node levels were dissected.
  • All six sonographic findings were significantly more frequent in metastatic lymph nodes in the lateral group.
  • However, in the central group, only two criteria-calcification and abnormal Doppler pattern-were found to significantly predict the presence of metastasis.
  • [MeSH-minor] Adult. Aged. Female. Humans. International Classification of Diseases. Korea / epidemiology. Male. Middle Aged. Neoplasm Staging / statistics & numerical data. Preoperative Care / methods. Reproducibility of Results. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] AJR Am J Roentgenol. 2009 Mar;192(3):560
  • (PMID = 19098181.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Saze Z, Terashima M, Otani S, Soeta N, Kashimura S, Osuka F, Odashima Y, Saito T, Hoshino Y, Kogure M, Hashimoto Y, Watanabe K, Gotoh M: [A case of advanced gastric cancer responding remarkably to neo-adjuvant combination chemotherapy using CPT-11 plus S-1]. Gan To Kagaku Ryoho; 2007 Sep;34(9):1473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer responding remarkably to neo-adjuvant combination chemotherapy using CPT-11 plus S-1].
  • Adjuvant chemotherapy for advanced gastric cancer has not yet been established.
  • We report a patient with advanced gastric cancer responding remarkably to neo-adjuvant combination chemotherapy consisting of CPT-11 and S-1.
  • The patient was a 69-year-old woman diagnosed with large type 3 advanced gastric cancer with esophageal invasion and having No.3 lymph node metastasis (cT3, cN1, cM0, cStage IIIA), treated with 2 courses of CPT-11 plus S-1 as neo-adjuvant chemotherapy.
  • Computed tomography after neo-adjuvant chemotherapy showed improvement of gastric wall thickness and reduction of lymph node metastasis.
  • There was no lymph node swelling,so we performed curative surgery consisting of total gastrectomy, splenectomy, cholecystectomy, and D 2 lymph node dissection.
  • Histological diagnosis was pT2 (MP), pN1, pStage II, and estimation of the histological change by chemotherapy was Grade 2.
  • Combination chemotherapy consisting of CPT-11 plus S-1 can be performed safely as a neo-adjuvant treatment, and may be an effective treatment modality for advanced gastric cancer.
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Combinations. Female. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Oxonic Acid / administration & dosage. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876149.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Lim JH, Lee JW, Kim EJ, Lee JI, Jeong S, Lee DH, Shin YW, Kim JM: [A case of recurred small hepatocellular carcinoma as a solitary lymph node metastasis after hepatic resection]. Korean J Gastroenterol; 2007 Jul;50(1):66-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurred small hepatocellular carcinoma as a solitary lymph node metastasis after hepatic resection].
  • However, solitary local lymph node recurrence in small HCC is rarely reported with suitable treatment modality being uncertain.
  • We herein, present a case of 60-year-old female patient with small HCC showing late lymph node metastasis after complete resection of primary HCC.
  • Eight months later, CT and PET scan revealed a 4.5 cm-sized portocaval lymph node (LN).
  • In addition, whole body PET/CT scan strongly suggested a solitary tumor recurrence.
  • Tumor was confirmed as LN metastasis from HCC by excisional histopathological examination.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172362.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


26. Takeuchi H, Kitagawa Y: [Preoperative diagnosis of lymph node metastases and sentinel node navigation surgery in patients with upper gastrointestinal cancer]. Nihon Geka Gakkai Zasshi; 2008 Mar;109(2):90-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative diagnosis of lymph node metastases and sentinel node navigation surgery in patients with upper gastrointestinal cancer].
  • In spite of recent advances in diagnostic tools such as computed tomography, endoscopic ultrasonography, and positron-emission tomography, preoperative diagnosis of lymph node metastases in patients with upper gastrointestinal (GI) cancer has been problematic because of the low sensitivity and accuracy in the detection of micrometastases.
  • To overcome this issue, the sentinel node (SN) concept has attracted attention in recent years and is anticipated to become a novel diagnostic tool for the identification of clinically undetectable lymph node metastases in patients with early upper GI cancer.
  • For early-stage gastric cancer, in which a better prognosis can generally be achieved using conventional surgical approaches, individualized, minimally invasive gastrectomy based on a combination of laparoscpic surgery with SN navigation surgery should be established as the next surgical milestone.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / surgery. Imaging, Three-Dimensional / methods. Sentinel Lymph Node Biopsy / methods. Surgery, Computer-Assisted / methods
  • [MeSH-minor] Endoscopy, Gastrointestinal / methods. Humans. Lymphatic Metastasis. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409586.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


27. Marx AH, Zielinski M, Kowitz CM, Dancau AM, Thieltges S, Simon R, Choschzick M, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Brümmendorf TH, Fiedler W, Bokemeyer C, Izbicki JR, Sauter G: Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology; 2010 Sep;57(3):418-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The epidermal growth factor receptor (EGFR) is a tyrosine kinase (TK) involved in the tumour progression of many cancer types and may serve as an important therapeutic target (erlotinib, cetuximab).
  • METHODS AND RESULTS: Tissue microarray (TMA) sections of 112 BAC and 45 lymph node metastases were analysed for EGFR amplification and expression using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).
  • Identical EGFR amplification status was found in 29 primary tumours and 29 matched lymph node metastases.
  • Moreover, FISH analysis of three to 16 large sections from all amplified BAC and corresponding lymph node metastases did not reveal any heterogeneity of EGFR amplification.
  • CONCLUSION: The high level and homogeneity of EGFR amplification in primary tumours and metastases suggests the potential therapeutic utility of anti-EGFR drugs in BAC.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20840671.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


28. Ojima H, Araki K, Kato T, Okamura K, Manda R, Hirayama I, Hosouchi Y, Nishida Y, Kuwano H: Clinicopathological characteristics and outcome indicators of stage II gastric cancer according to the Japanese classification of gastric cancer. Anticancer Res; 2006 Mar-Apr;26(2B):1385-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics and outcome indicators of stage II gastric cancer according to the Japanese classification of gastric cancer.
  • BACKGROUND: The characteristics of stage II gastric cancer according to the Japanese Classification of Gastric Cancer (JCGC) were examined and the high-risk factors predicting poor prognosis were detected.
  • PATIENTS AND METHODS: In total, 107 patients, who underwent clinically curative gastrectomy with D2 lymphadenectomy for stage II gastric cancer, were included.
  • Survival curves of the depth of invasion, lymph node metastasis, the ratio of involved: resected lymph nodes and chemotherapy treatment were compared.
  • RESULTS: The survival curves were related to tumor invasion depth and lymph node metastasis.
  • The ratio of involved resected lymph nodes was a good prognostic indicator compared to the classification of regional lymph node metastasis (N classification).
  • CONCLUSION: pT2pN1 (stage II) gastric cancers according to the JCGC, especially pSSpN1 cases, included stage IIIB and IV gastric cancers according to the International Union Against Cancer / American Joint Committee on Cancer (UICC/AJCC); therefore, the prognosis of these might be poor.
  • With pSSpN1 cases, according to the JCGC, anticancer chemotherapy equivalent to that required for stage III gastric cancer cases is necessary.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619548.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


29. Yaginuma Y, Unotoro J, Kamiyama H, Ishido Y, Kasamaki S, Sakamoto K, Shindo T, Ishibasi Y, Kamano T: Genomic copy-number aberrations related to lymph-node metastasis of colon cancer. J Int Med Res; 2006 Jul-Aug;34(4):390-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic copy-number aberrations related to lymph-node metastasis of colon cancer.
  • Lymph-node metastasis is an important indicator in the diagnosis of colon cancer.
  • In order to determine the genes involved in metastasis, genomic copy-number aberrations in the primary tumours and lymph-node metastases were analysed in 12 patients using comparative genomic hybridization.
  • Copy-number gains at 6p12 and losses at 8p12 were observed in a greater number of the primary tumours than in the metastases.
  • These aberrations appear to be involved in lymph-node metastasis of colon cancer, and may allow measurement of the risk of lymph-node metastasis from a given colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Colonic Neoplasms / genetics. Lymph Nodes / pathology. Lymphatic Metastasis / genetics
  • [MeSH-minor] Chromosomes, Human, Pair 6. Chromosomes, Human, Pair 8. DNA, Neoplasm / analysis. Female. Gene Amplification. Gene Dosage. Genome. Humans. Male. Nucleic Acid Hybridization

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989495.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


30. Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L, Zheng X, Sun J, Lu B, Zhang X: Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother; 2010 Nov;59(11):1707-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer.
  • To establish the prognostic value of B7-H4 expression by tumor cells in gastric cancer patients, we evaluated the association of B7-H4 expression with clinicopathologic factors and overall survival of gastric cancer patients.
  • A retrospective cohort study including 156 gastric cancer patients was performed in the present report.
  • Immunohistochemical assay was used to evaluate the expression of B7-H4 in the surgical specimens of gastric cancer tissues.
  • B7-H4 expression in the gastric cancer cells was observed in about 44.9% gastric cancer specimens.
  • Univariate analysis demonstrated that there was no correlation between B7-H4 expression and sex, age, histological type, pathological grade or tumor size.
  • In contrast, B7-H4 expression correlated positively with cancer invasiveness and lymph node metastasis.
  • The present study demonstrated that higher B7-H4 expression in cancer cells was associated with poor prognosis of gastric cancer patients.
  • This is consistent with the idea that B7-H4 promotes cancer progression, likely via inhibition of anti-tumor immune responses.
  • [MeSH-minor] Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Survival Rate. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20725832.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


31. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y: International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int; 2010 May;105(10):1402-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To externally validate the prognostic value of lymphovascular invasion (LVI) in a large international cohort of patients treated with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB).
  • RESULTS: LVI was detected in 1407 patients (33.1%); the proportion of LVI increased with advancing stage, higher grade, soft-tissue surgical margin involvement, and lymph node metastasis (P < 0.001 for all).
  • In standard multivariate models, LVI was associated with both disease recurrence (hazard ratio 1.43, P < 0.001) and cancer-specific mortality (1.45, P < 0.001).
  • In the entire cohort, adding LVI to a base model that included standard features improved only minimally its predictive accuracy for both recurrence and cancer-specific mortality (by 1.1% and 1.2%, respectively).
  • In 3122 patients with negative lymph nodes, LVI remained independently associated with and improved the predictive accuracy of the standard predictors for recurrence (hazard ratio 1.68, P < 0.001; +2.3%) and cancer-specific mortality (1.70, P < 0.001; +2.4%).
  • By contrast, in 1071 node-positive patients, LVI only marginally improved the prediction of cancer-specific recurrence (hazard ratio 1.20, P < 0.001; +0.2%) and survival (1.23, P < 0.001; +0.5%).
  • CONCLUSIONS: LVI is strongly associated with clinical outcome in node-negative patients treated with RC.
  • [MeSH-minor] Aged. Female. Humans. Lymph Node Excision / mortality. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132195.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


32. Moo TA, Umunna B, Kato M, Butriago D, Kundel A, Lee JA, Zarnegar R, Fahey TJ 3rd: Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. Ann Surg; 2009 Sep;250(3):403-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma.
  • Of these, 45 had right and left central neck lymph node basins submitted separately for pathologic examination.
  • We examined the laterality of positive lymph nodes based on tumor location and size.
  • RESULTS: Overall, positive lymph nodes were found in 45% of patients.
  • Of the patients having a lateralized CND, 33% had ipsilateral positive nodes only, while 20% had bilateral positive nodes.
  • None of the patients with tumor size <=1 cm had bilateral positive lymph nodes compared with 31% of patients with tumors >1 cm (P = 0.02).
  • Multifocality did not affect lymph node metastasis in tumors <=1 cm.
  • In tumors >1 cm, bilateral CND should be considered as these patients are more likely to have bilateral positive nodes.
  • If tumor size is used as criteria for prophylactic CND, approximately one-third of patients can be spared a bilateral CND.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Lymph Node Excision / methods. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Chi-Square Distribution. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Postoperative Complications / epidemiology. Prospective Studies. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2010 Oct;252(4):706-7 [20881780.001]
  • (PMID = 19661784.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Nash GM, Weiser MR, Guillem JG, Temple LK, Shia J, Gonen M, Wong WD, Paty PB: Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum; 2009 Apr;52(4):577-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after transanal excision of T1 rectal cancer.
  • PURPOSE: Several series report higher recurrence after transanal excision of T1 rectal cancer than after radical resection.
  • However, the impact of transanal excision on cancer mortality has not been adequately studied.
  • METHODS: Patients with transanal excision or radical resection for T1 rectal cancer treated between 1985 and 2004 were identified from a prospective database.
  • The transanal excision group was notable for older mean age (64 vs. 59 years), shorter mean distance from anal verge (5.9 vs. 7.8 cm), and smaller tumor size (2.3 vs. 3.1 cm).
  • Twenty percent of radical resection specimens had lymph node metastasis.
  • Local recurrence was noted in a higher proportion of transanal excision patients (13.2 vs. 2.7 percent, P = 0.001).
  • CONCLUSIONS: Transanal excision offers inferior oncologic results, including greater risk of cancer-related death.
  • [MeSH-minor] Adult. Aged. Digestive System Surgical Procedures / methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404055.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Li S, Xu H, Ding H, Huang Y, Cao X, Yang G, Li J, Xie Z, Meng Y, Li X, Zhao Q, Shen B, Shao N: Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J Pathol; 2009 Jul;218(3):327-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a new in situ tissue slide-based SELEX strategy targeting neoplastic tissues from breast cancer patients.
  • The aptamers may be used as new molecular probes for pathological diagnosis and tumour imaging, and also to reveal the molecular differences that are responsible for the diseases.
  • After 12 rounds of selection, using the paraffin tissue sections from infiltrating ductal carcinomas as targets, and using the adjacent normal tissue from the same case as controls, one of the enriched ssDNA aptamers, BC15, was selected from a nucleic acid library and characterized as recognizing breast cancer cells either within the tissue sections or from the culture medium, but only weakly binding to adjacent normal cells or immortalized breast cell line MCF10A.
  • BC15 aptamer was also used to probe cancer cells in tissues from other pathological types of breast cancers including lobular carcinoma, ductal carcinoma complicated with lobular carcinoma, comedo carcinoma, and lymph node metastasis of breast ductal carcinoma origin or breast lobular carcinoma origin.
  • Therefore, tissue slide-based SELEX holds promise in identifying tumour markers and developing specific molecular probes for cancer diagnosis.
  • [MeSH-major] Aptamers, Nucleotide / genetics. Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Heterogeneous-Nuclear Ribonucleoprotein Group A-B / genetics
  • [MeSH-minor] Amino Acid Sequence. Biopsy. DNA, Neoplasm / genetics. Female. Gene Library. Humans. Microscopy, Confocal. Molecular Sequence Data. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. SELEX Aptamer Technique / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 19291713.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Heterogeneous-Nuclear Ribonucleoprotein Group A-B; 0 / Neoplasm Proteins; 0 / hnRNP A1
  •  go-up   go-down


35. Kong LL, Cui W, Wang XC, Wang X, Yang QY, Song XY, Jiang XG, Yan CY: [Expression of MMP-2 and its clinical significance in cervical squamous carcinoma]. Beijing Da Xue Xue Bao; 2008 Dec 18;40(6):583-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the relationship of the expression of matrix metalloproteinase-2 (MMP-2) with tumorigenesis, development and metastasis of cervical squamous carcinoma.
  • In SCC, MMP-2 protein was expressed in 91.30%(21/23) of patients, which positively correlated with lymph node metastasis significantly (P<0.05).
  • CONCLUSION: The positive expression of MMP-2 can be used to estimate the metastatic potentiality and help the adjuvant treatment.
  • MMP-2 is related well with the occurrence, invasion and metastasis of cervical squamous carcinoma.
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism


36. Kato T, Steers G, Campo L, Roberts H, Leek RD, Turley H, Kimura T, Kameoka S, Nishikawa T, Kobayashi M, Harris AL, Gatter KC, Pezzella F: Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer. Br J Cancer; 2007 Nov 5;97(9):1277-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer.
  • British patients were significantly older (56.3+/-11.4 years vs 52.5+/-12.9 years; P<0.01) and had smaller tumours (2.2+/-1.3 vs 2.7+/-1.8 cm; P<0.01), which were more frequently oestrogen receptor positive (78.8 vs 57.2%, P<0.01), had more grade III tumours (29.9 vs 21.4%, P=0.04) and more infiltrating lobular carcinomas (13.6 vs 4.0%, P<0.01) and a higher MVD compared with Japanese patients (57.9+/-19.8 vs 53.2+/-18.6; P=0.01).
  • However, no difference in the prevalence of lymph-node metastasis was found between them (39.1 vs 37.5%, P=0.75).
  • The present study shows that MVD contributes to the Japanese-British disparity in breast cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aging / physiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Great Britain. Humans. Japan. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Detect Prev. 1999;23(6):463-73 [10571656.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1635-44 [16217757.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Feb;37(2):97-114 [11166583.001]
  • [Cites] Breast Cancer Res Treat. 2001 Nov;70(1):65-74 [11767005.001]
  • [Cites] J Nutr. 2002 Aug;132(8):2307-11 [12163680.001]
  • [Cites] Oncology. 2003;64(2):146-53 [12566912.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1900-8 [12799634.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):241-5 [12865469.001]
  • [Cites] Breast Cancer. 2003;10(4):312-9 [14634509.001]
  • [Cites] Histopathology. 2004 May;44(5):428-36 [15139990.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Int J Cancer. 1976 Sep 15;18(3):269-73 [955744.001]
  • [Cites] Arch Surg. 1980 Sep;115(9):1056-62 [6251779.001]
  • [Cites] J Surg Oncol. 1988 Nov;39(3):206-9 [3054337.001]
  • [Cites] Int J Cancer. 1989 Nov 15;44(5):770-6 [2583858.001]
  • [Cites] Am J Epidemiol. 1990 Jun;131(6):961-72 [2188501.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Breast Cancer Res Treat. 1991 May;18 Suppl 1:S19-22 [1873552.001]
  • [Cites] Breast Cancer Res Treat. 1991 May;18 Suppl 1:S73-6 [1873561.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Lancet. 1992 Jan 4;339(8784):1-15 [1345950.001]
  • [Cites] Am J Epidemiol. 1992 Mar 15;135(6):609-18 [1580237.001]
  • [Cites] Lancet. 1992 Nov 7;340(8828):1120-4 [1279332.001]
  • [Cites] Eur J Cancer. 1993;29A(8):1141-5 [8390846.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):454-66 [7509851.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):705-12 [7908990.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1297-301 [7779727.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1642-3 [7783561.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 5;87(13):997-1008 [7543156.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1181-4 [7590689.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1196-200 [7590692.001]
  • [Cites] J Pathol. 1995 Nov;177(3):275-83 [8551390.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):308-14 [8625239.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(1):19-31 [10206069.001]
  • [Cites] Int J Cancer. 1999 Jun 21;84(3):278-83 [10371347.001]
  • [Cites] Surg Gynecol Obstet. 1963 Aug;117:196-200 [14048012.001]
  • [Cites] Breast Cancer. 2004;11(2):156-9 [15550861.001]
  • [Cites] Cancer Sci. 2005 Jan;96(1):57-62 [15649257.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2172-84 [15800310.001]
  • [Cites] Pac Health Dialog. 2004 Sep;11(2):146-53 [16281692.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):758-9 [16377739.001]
  • [Cites] Int J Cancer. 2000 Jan 20;89(1):74-80 [10719734.001]
  • (PMID = 17923874.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2360458
  •  go-up   go-down


37. Başaran B, Aslan I, Tinaz ME, Başerer N, Yazicioğlu E: Oncological results of surgical treatment of malignant tumors of the nasal vestibule. Kulak Burun Bogaz Ihtis Derg; 2007;17(3):133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncological results of surgical treatment of malignant tumors of the nasal vestibule.
  • Based on the classification system of the AJCC 1992 for skin cancers, and the UICC classification for neck metastasis, three patients had T2, three patients had T3, and four patients had T4 tumors.
  • Lymph node metastasis was present in three patients.
  • RESULTS: Three patients with metastatic neck disease and four patients with advanced tumors underwent radical neck dissection and selective supraomohyoid neck dissection, respectively.
  • Another patient died in the postoperative third year due to metastatic squamous cell carcinoma of the lung.
  • Two patients with advanced tumors had nasal ventilation problems and a secondary revision procedure was required in one.
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Incidence. Male. Medical Records. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Sex Factors. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873502.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


38. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf); 2006 Sep;65(3):364-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with antithyroglobulin antibodies and those with extracervical metastases at presentation were excluded.
  • While univariate analysis showed the BRAF(V600E) mutation was associated with tumour recurrence (21% with mutation vs 7% without mutation; P = 0.037), this association was not shown following multivariate analyses adjusting for the clinicopathological prognostic factors of age, gender, tumour size, extrathyroid extension, multifocality and lymph node metastasis.
  • [MeSH-major] Carcinoma, Papillary / genetics. Neoplasm Recurrence, Local / genetics. Point Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918957.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


39. Kobayashi O, Tsuburaya A, Yoshikawa T, Osaragi T, Murakami H, Yoshida T, Sairenji M: The efficacy of gastrectomy for large gastric cancer. Int J Clin Oncol; 2006 Feb;11(1):44-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of gastrectomy for large gastric cancer.
  • BACKGROUND: Large gastric cancer (LGC) is frequently associated with extended disease, and the role of surgical resection has been debated.
  • The clinicopathological features, the status of the residual tumor, the incidence and patterns of relapse, and the survival were analyzed.
  • The numbers of patients with tumors of T3 or greater, lymph node involvement, and peritoneal metastases were 356 (86%), 359 (87%), and 126 (30%), respectively.
  • One hundred and eighty-eight patients (45%) underwent incomplete tumor resection (R2).
  • The R2/R0 (no residual tumor) ratio was greater than 1 in patients with type 4 tumors and N1 or greater metastasis and in those with type 3 tumors and N2 or greater metastasis.
  • The survival rates were inversely related to the tumor type, size, and lymph node metastasis.
  • In the 216 patients with R0, the 5-year survivals of those with pN (International Union Against Cancer [UICC] classification) 0, 1, 2, and 3 were 66%, 56%, 36%, and 5%, respectively (P = 0.001).
  • In 96 of these 216 patients (44%) the tumor recurred, and peritoneal metastasis was the most frequent mode of recurrence (48%).
  • By Cox's proportional hazard model, the tumor size was an independent prognostic factor.
  • [MeSH-minor] Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Feb 15;82(4):621-31 [9477092.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1796-800 [10760754.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Nov;30(12):1933-40 [14650962.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):558-62 [10492627.001]
  • [Cites] J Surg Oncol. 1992 Oct;51(2):104-8 [1405648.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2282-7 [12805327.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] Gastric Cancer. 2002;5(4):201-7 [12491077.001]
  • [Cites] World J Surg. 1987 Aug;11(4):418-25 [3630186.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1113-9 [12945079.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1521-5 [15083179.001]
  • [Cites] Eur J Surg Oncol. 1992 Jun;18(3):287-92 [1607042.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:24-7 [12775016.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44 [8230264.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Ann Surg Oncol. 1997 Mar;4(2):137-40 [9084850.001]
  • [Cites] Oncology. 1995 Jan-Feb;52(1):35-40 [7800340.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3673-7 [12552975.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1318-26 [2769330.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):57-63 [11957072.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:40-4 [12775019.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):873-7 [11412261.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1297-301 [15865081.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1509-12 [11677997.001]
  • (PMID = 16508728.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Khayyata S, Basturk O, Adsay NV: Invasive micropapillary carcinomas of the ampullo-pancreatobiliary region and their association with tumor-infiltrating neutrophils. Mod Pathol; 2005 Nov;18(11):1504-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinomas of the ampullo-pancreatobiliary region and their association with tumor-infiltrating neutrophils.
  • The mean tumor size was 3.2 cm.
  • Lymph node metastasis was detected in 11/15 cases.
  • In nine cases, there was abundant inflammation composed of neutrophils concentrating around the tumor cells, both intraepithelial ('cannibalism') and stromal.
  • Molecules implicated in abnormalities of tumor cell-stroma adhesion, galectin-3 and E-cadherin were expressed in the cytoplasm of 11/11 and 9/11 cases, respectively.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens / metabolism. Antigens, Neoplasm. Cadherins / metabolism. Female. Galectin 3 / metabolism. Glycoproteins / metabolism. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged. Mucin-1. Mucins / metabolism. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Modern Pathology (2005) 18, 1504-1511. doi:10.1038/modpathol.3800460; published online 8 July 2005.
  • (PMID = 16007065.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Cadherins; 0 / Galectin 3; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  •  go-up   go-down


41. Ariyoshi Y, Miyatake S, Kimura Y, Shimahara T, Kawabata S, Nagata K, Suzuki M, Maruhashi A, Ono K, Shimahara M: Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep; 2007 Oct;18(4):861-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis.
  • The purpose of this clinical trial was to evaluate the utility of boron neutron capture therapy (BNCT) using epithermal neutrons for cases of recurrent cancer in the oral cavity, which are not indicated for a conventional treatment modality.
  • We enrolled four patients with local recurrence or metastasis to the regional lymph nodes after completion of initial treatments, including surgery, chemotherapy and radiotherapy.
  • Our results suggested that BNCT is a useful treatment modality for recurrent or regionally metastasized oral cancer.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Neutrons
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Boron Compounds / therapeutic use. Carcinoma, Mucoepidermoid / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Head and Neck Neoplasms / radiotherapy. Humans. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786347.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Boron Compounds
  •  go-up   go-down


42. Likui W, Hong W, Shuwen Z: Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg; 2010 Jan;14(1):74-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer.
  • OBJECTIVE: Osteopontin (OPN) is a phosphorylated glycoprotein which is associated with tumor progression, development, and metastasis.
  • Recently, it has been reported that OPN is highly upregulated in a variety of human malignancies.
  • The aim of this study is to investigate the clinical significance of OPN mRNA expression in colorectal cancer (CRC).
  • Real-time quantitative RT-PCR assay was performed to analyze the expression of OPN mRNA in 82 CRC tissue samples and corresponding non-tumor tissues.
  • Moreover, the results of real-time quantitative RT-PCR and immunohistochemistry showed that the expression levels of OPN mRNA and protein in tumor tissues were significantly higher than those in the corresponding non-tumor tissues (P < 0.001).
  • The expression level of OPN mRNA was significantly correlated with lymph node metastasis, lymphatic or venous invasion, and TNM stage (P = 0.0033, 0.0061, 0.0008, and 0.0012, respectively).
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Line. Cell Line, Tumor. Disease-Free Survival. Female. Gene Expression. Humans. Intestinal Mucosa / cytology. Male. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biotechniques. 1991 Sep;11(3):304, 306, 308 [1718327.001]
  • [Cites] Mol Ther. 2009 Jan;17(1):153-61 [18985031.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] Gastroenterology. 2008 Sep;135(3):956-68 [18555021.001]
  • [Cites] Carcinogenesis. 2005 Apr;26(4):741-51 [15661802.001]
  • [Cites] Invasion Metastasis. 1997;17(1):1-15 [9425320.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):515-23 [15679049.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1717-23 [17565744.001]
  • [Cites] Cancer Lett. 2005 Jan 10;217(1):87-95 [15596299.001]
  • [Cites] J Natl Med Assoc. 2008 Dec;100(12):1441-4 [19110912.001]
  • [Cites] Cancer Invest. 2009 Mar;27(3):313-23 [19194826.001]
  • [Cites] Biotechniques. 1993 Mar;14(3):448-53 [7681300.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):85-90 [12650611.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1087-97 [17548669.001]
  • [Cites] Cancer Sci. 2008 Oct;99(10):1901-7 [19016748.001]
  • [Cites] Proc Assoc Am Physicians. 1997 Jan;109(1):1-9 [9010911.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2928-35 [17504993.001]
  • [Cites] Crit Rev Oral Biol Med. 2000;11(3):279-303 [11021631.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3419-27 [17896150.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:723-49 [11264474.001]
  • [Cites] Gastroenterology. 2009 Oct;137(4):1358-66.e1-3 [19549529.001]
  • [Cites] J Oral Pathol Med. 2007 Jan;36(1):30-4 [17181739.001]
  • [Cites] J Eval Clin Pract. 2008 Jun;14(3):407-15 [18373578.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2007 Aug;29(8):591-5 [18210878.001]
  • [Cites] World J Surg. 2008 Sep;32(9):1989-95 [18629582.001]
  • [Cites] Ann N Y Acad Sci. 1995 Apr 21;760:127-42 [7540371.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):404-7 [17152482.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):103-18 [18049863.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):861-70 [19189191.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):1033-49 [9715162.001]
  • [Cites] Hepatology. 2008 Dec;48(6):1834-42 [18972404.001]
  • (PMID = 19763701.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 106441-73-0 / Osteopontin
  •  go-up   go-down


43. Wickborn C, Klein-Szanto AJ, Schlag PM, Braunewell KH: Correlation of visinin-like-protein-1 expression with clinicopathological features in squamous cell carcinoma of the esophagus. Mol Carcinog; 2006 Aug;45(8):572-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EF-hand Ca(2+)-sensor proteins are key molecules for transducing Ca(2+) signals into physiological answers and changes in cytosolic Ca(2+) concentration control a variety of cellular responses, including proliferation, migration, and differentiation, which are relevant for tumor progression.
  • The Ca(2+)-sensor visinin-like protein-1 (VILIP-1) has recently attracted major interest due to its putative tumor suppressor function.
  • Whereas VILIP-1 is expressed in normal skin, it is downregulated in skin tumors in a murine tumor model.
  • The aim of this study was to investigate the expression of the Ca(2+)-sensor VILIP-1 in squamous cell carcinoma of the esophagus and to correlate expression levels with clinicopathological features of the tumor.
  • VILIP-1 expression was completely lost or significantly reduced in esophageal tumor tissue compared with normal squamous epithelium.
  • Correlation with clinicopathological features indicated that there was significantly less VILIP-1 expression in lymph node positive (N = 1) versus lymph node negative (N = 0) tumors (P = 0.002).
  • Although there was no significant difference between highly (G(1)), moderately (G(2)) and poorly differentiated (G(3)) tumors (P = 0.177), VILIP-1 expression in tumors is significantly correlated with the depth of tumor invasion (P = 0.028 between T1, T2, T3, and T4).
  • In contrast, co-staining with the proliferation marker Ki-67 indicated no significant correlation with proliferation rates in tumors (Ki-67 index of the tumor).
  • The protein expression level significantly correlates with invasive features, such as depth of tumor invasion and local lymph node metastasis, but not with proliferation rate of tumor cells.
  • [MeSH-minor] Aged. Aged, 80 and over. Calcium Signaling. Female. Humans. Ki-67 Antigen / analysis. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683251.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA107257
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neurocalcin; 0 / VSNL1 protein, human
  •  go-up   go-down


44. Costante G, Filetti S: Diagnosis: Thyroglobulin in fine-needle aspirates-a clue to metastasis? Nat Rev Endocrinol; 2009 May;5(5):249-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis: Thyroglobulin in fine-needle aspirates-a clue to metastasis?
  • Clinical investigation of enlarged, local lymph nodes after surgery for papillary thyroid carcinoma is problematic.
  • Use of the fine-needle aspiration thyroglobulin assay could help to identify patients whose disease has progressed to lymph-node metastasis.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Lymphatic Metastasis / diagnosis. Thyroglobulin

  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444256.001).
  • [ISSN] 1759-5037
  • [Journal-full-title] Nature reviews. Endocrinology
  • [ISO-abbreviation] Nat Rev Endocrinol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


45. Oyama N: Editorial comment on: Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol; 2007 Aug;52(2):429
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.
  • [MeSH-major] Lymphatic Metastasis / radiography. Lymphatic Metastasis / radionuclide imaging. Prostatic Neoplasms / radiography. Prostatic Neoplasms / radionuclide imaging. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. Choline. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Predictive Value of Tests. Prospective Studies. Prostate-Specific Antigen / blood. Prostatectomy. Radiopharmaceuticals. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur Urol. 2007 Aug;52(2):423-9 [17397992.001]
  • (PMID = 17397993.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; EC 3.4.21.77 / Prostate-Specific Antigen; N91BDP6H0X / Choline
  •  go-up   go-down


46. Thelen A, Scholz A, Benckert C, Weichert W, Dietz E, Wiedenmann B, Neuhaus P, Jonas S: Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. Ann Surg Oncol; 2008 Mar;15(3):791-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma.
  • BACKGROUND: Tumor-associated lymphangiogenesis has been shown to promote nodal spread and is of prognostic significance in some tumor entities.
  • Tumors with a high LVD (34 out of 60) had a significant higher incidence of lymph node involvement (p < 0.001), perivascular (p = 0.017), and perineural (p = 0.033) lymphangiosis and local recurrence (p < 0.001).
  • CONCLUSIONS: Lymphangiogenesis is associated with increased frequency of tumor cells in lymphatics and lymph nodes in hilar cholangiocarcinoma.
  • The prognostic importance of tumor-associated lymphangiogenesis was reflected by LVD serving as an independent prognostic factor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172731.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Sohn DK, Chang HJ, Park JW, Choi DH, Han KS, Hong CW, Jung KH, Kim DY, Lim SB, Choi HS, Jeong SY: Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol; 2007 Aug;60(8):912-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type.
  • AIMS: To evaluate the histopathological risk factors for lymph node metastasis in cases of pedunculated or semipedunculated submucosal invasive colorectal carcinoma (SICC).
  • METHODS: A total of 48 patients with non-sessile SICC who underwent systematic lymph node dissection were included.
  • RESULTS: Lymph node metastasis was observed in seven cases (14.6%).
  • Univariate analysis showed angiolymphatic invasion and tumour budding to be significantly associated with lymph node metastasis.
  • Multivariate analysis showed that tumour budding was the only independent factor associated with lymph node metastasis in cases of non-sessile SICC.
  • CONCLUSIONS: Results indicate that tumour budding is a useful risk factor for predicting lymph node metastasis in cases of pedunculated or semipedunculated SICC.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Cell Differentiation. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1983 Oct;7(7):613-23 [6638257.001]
  • [Cites] Int J Clin Oncol. 2006 Feb;11(1):1-8 [16508722.001]
  • [Cites] Gastroenterology. 1985 Aug;89(2):328-36 [4007423.001]
  • [Cites] Gastroenterology. 1986 Aug;91(2):419-27 [3721127.001]
  • [Cites] Prog Clin Biol Res. 1988;279:89-99 [3054934.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1052-5 [11036281.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2882-91 [12115376.001]
  • [Cites] Jpn J Clin Oncol. 2002 Oct;32(10):412-6 [12451038.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):388-91 [12749229.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1054-9 [12907899.001]
  • [Cites] Mod Pathol. 2004 May;17(5):503-11 [15001992.001]
  • [Cites] J Gastroenterol. 2004 Jun;39(6):534-43 [15235870.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):385-94 [15300569.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):832-9 [15492565.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):323-8 [1848810.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):455-61 [8261988.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1179-86 [8826938.001]
  • [Cites] Gastrointest Endosc. 1996 Nov;44(5):594-7 [8934168.001]
  • [Cites] World J Surg. 1997 Sep;21(7):694-701 [9276699.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):1032-9; discussion 1039-40 [15585391.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):92-100 [15690664.001]
  • [Cites] Gut. 1984 May;25(5):437-44 [6714785.001]
  • (PMID = 16997919.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1994481
  •  go-up   go-down


48. Yang YL, Chu JY, Luo ML, Wu YP, Zhang Y, Feng YB, Shi ZZ, Xu X, Han YL, Cai Y, Dong JT, Zhan QM, Wu M, Wang MR: Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer; 2008 Feb;47(2):127-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma.
  • Positive correlation was found only for PRKCI between amplification and tumor size (P = 0.043), lymph node metastasis (P = 0.015) and clinical stage (P = 0.002).
  • Statistical analysis revealed that PRKCI overexpression was correlated with lymph node metastasis (P = 0.002) and higher stage (P = 0.004).
  • Performing multivariate logistic regression analysis, a significant association between PRKCI overexpression and presence of lymph node metastasis was found, which was independent of T-stage of the primary tumors (P = 0.004).
  • Our results indicate that PRKCI is an attractive target in the 3q26 amplicon and that it may serve as a molecular marker for metastasis and occult advanced tumor stages in ESCC.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / enzymology. Chromosomes, Human, Pair 3 / genetics. Esophageal Neoplasms / enzymology. Gene Amplification. Isoenzymes / genetics. Protein Kinase C / genetics
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Female. Gene Dosage. Humans. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17990328.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda
  •  go-up   go-down


49. Kawaguchi T, Mayama I, Iwabuchi I, Ogasawara M, Tsukui A: [Chemo-endocrine therapy with low-dose cisplatin, UFT, and dexamethasone for hormone-refractory prostate cancer patients]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1921-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemo-endocrine therapy with low-dose cisplatin, UFT, and dexamethasone for hormone-refractory prostate cancer patients].
  • Since September 2005, twenty-two patients with hormone-refractory prostate cancer (aged 55-81 years) were treated with LH-RH agonist and low-dose cisplatin, UFT, and dexamethasone after proving resistant to estramustine phosphate therapy.
  • All patients suffered from clinical progression such as local recurrence in 11 patients who had already received radiation therapy, lymph node metastasis in 7 patients, and bone metastasis in 15 patients.
  • The follow-up term ranged from 2 to 43 months, and nine patients died of cancer progression.
  • We considered this therapy to be effective for patients with hormone-refractory prostate cancer because it maintained their good QOL.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948257.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 33515-09-2 / Gonadotropin-Releasing Hormone; 56HH86ZVCT / Uracil; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; 1-UFT protocol
  •  go-up   go-down


50. Lee K, Jung ES, Choi YJ, Lee KY, Lee A: Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma. J Korean Med Sci; 2010 Oct;25(10):1449-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclin D1 expression was associated with tumor stage and recurrence (P=0.017 and P=0.036, respectively).
  • As determined by multivariate analysis, tumor stage, lymph node metastasis and the combined expression of p53 and pRb are independent prognostic factors.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Retinoblastoma Protein / metabolism. Tumor Suppressor Protein p53 / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Recurrence. Survival Rate

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Oncol. 2007 Nov-Dec;25(6):468-75 [18047954.001]
  • [Cites] Mod Pathol. 2007 Apr;20(4):445-59 [17384651.001]
  • [Cites] J Korean Med Sci. 2009 Dec;24(6):995-1003 [19949651.001]
  • [Cites] J Urol. 2010 Jan;183(1):68-75 [19913255.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):1025-9 [11029508.001]
  • [Cites] Mol Pathol. 2001 Aug;54(4):215-21 [11477133.001]
  • [Cites] Oncogene. 2002 Jul 11;21(30):4680-90 [12096344.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1014-24 [14981102.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1007-13 [14981105.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):552-7 [15226775.001]
  • [Cites] Int J Cancer. 1993 Mar 12;53(5):781-4 [8449603.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1057-68 [9298882.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1090-4 [9515785.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1615-21 [9811354.001]
  • [Cites] Oncogene. 1999 Feb 4;18(5):1197-203 [10022125.001]
  • [Cites] Urol Res. 2004 Dec;32(6):373-85 [15551095.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] BJU Int. 2008 Jul;102(1):15-22 [18325050.001]
  • (PMID = 20890425.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2946654
  • [Keywords] NOTNLM ; Cyclin D1 / Urothelial Carcinoma / p16 / p53 / pRb
  •  go-up   go-down


51. Hsu CG, Lin LY, Ko JL, Yang SF, Chang H, Lin CY, Tsai HT, Chen SC, Chen SC, Wang PH: High expression of human nonmetastatic clone 23 type 1 in cancer of uterine cervix and its association with poor cell differentiation and worse overall survival. J Surg Oncol; 2008 Nov 1;98(6):448-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of human nonmetastatic clone 23 type 1 in cancer of uterine cervix and its association with poor cell differentiation and worse overall survival.
  • BACKGROUND AND OBJECTIVES: The role of human nonmetastatic clone 23 type 1 (nm23-H1), a metastasis-associated gene, is less clear-cut in cancer of uterine cervix; therefore, we investigate its expression in cancer tissues and its correlation with clinicopathologic variables and survival of patients.
  • METHODS: Thirty cervical cancer tissues and their normal counterparts were collected to evaluate quantitative nm23-H1 mRNA expression.
  • From them, 16 cancer and 16 normal tissues were collected and added with another 64 cancer tissues to construct a 96-tissue core microarray for immunohistochemical study.
  • We evaluated the relationships among nm23-H1 immunostaining using semi-quantitative H scores, clinicopathologic parameters, recurrence and survival in cervical cancer patients.
  • RESULTS: Nm23-H1 mRNA expression and H score (median H scores: 2.0 vs. 0.3, P = 0.001) were higher in cervical cancer tissues than normal counterparts, respectively.
  • Nm23-H1 expression was significantly associated with depth of stromal invasion (P = 0.003), tumor diameter (P = 0.044) and cell differentiation (P = 0.025).
  • Other than stage II, poor cell differentiation as well as positive parametrium invasion and lymph node metastasis, positive nm23-H1 expression was significantly correlated with poor overall survival.
  • CONCLUSION: High nm23-H1 expression is predictive of worse overall survival for cervical cancer patients.
  • [MeSH-minor] Cell Differentiation. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Polymerase Chain Reaction / methods. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18668641.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NM23 Nucleoside Diphosphate Kinases; 0 / RNA, Messenger; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


52. Maruyama R, Akino K, Toyota M, Suzuki H, Imai T, Ohe-Toyota M, Yamamoto E, Nojima M, Fujikane T, Sasaki Y, Yamashita T, Watanabe Y, Hiratsuka H, Hirata K, Itoh F, Imai K, Shinomura Y, Tokino T: Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis; 2008 Jul;29(7):1312-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer.
  • Gastric cancer cells often show altered Ras signaling, though the underlying molecular mechanism is not fully understood.
  • We examined the expression profile of eight ras-association domain family (RASSF) genes plus MST1/2 and found that RASSF2A is the most frequently downregulated in gastric cancer.
  • RASSF2A was completely silenced in 6 of 10 gastric cancer cell lines as a result of promoter methylation, and expression was restored by treating the cells with 5-aza-2'-deoxycytidine.
  • Introduction of RASSF2A into non-expressing cell lines suppressed colony formation and induced apoptosis.
  • In primary gastric cancers, aberrant methylation of RASSF2A was detected in 23 of 78 (29.5%) cases, and methylation correlated significantly with an absence of the lymphatic invasion, absence of venous invasion, absence of lymph node metastasis, less advanced stages, Epstein-Barr virus, absence of p53 mutations and the presence of the CpG island methylator phenotype-high.
  • These results suggest that epigenetic inactivation of RASSF2A is required for tumorigenesis in a subset of gastric cancers.
  • [MeSH-minor] Amino Acid Sequence. Cell Growth Processes / genetics. Cell Line, Tumor. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cytoplasm / genetics. Cytoplasm / metabolism. DNA Methylation. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):174-80 [10761704.001]
  • [Cites] Mol Carcinog. 2007 Oct;46(10):865-71 [17538946.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4353-7 [10969776.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3105-9 [11306494.001]
  • [Cites] Gene Ther. 2001 Sep;8(18):1401-8 [11571580.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37258-65 [11486009.001]
  • [Cites] Curr Biol. 2002 Apr 2;12(7):R259-61 [11937045.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2713-20 [11965544.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1817-23 [12087472.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6645-50 [12438262.001]
  • [Cites] Nature. 2002 Dec 12;420(6916):629-35 [12478284.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):95-8 [12957284.001]
  • [Cites] Hum Genet. 2003 Dec;114(1):118-20 [14513361.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8606-13 [14695171.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):689-99 [14742272.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]
  • [Cites] Semin Cancer Biol. 2004 Jun;14(3):195-200 [15246055.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6605-9 [2573419.001]
  • [Cites] Gastroenterology. 1990 Apr;98(4):955-60 [2179035.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):381-6 [1846312.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5815-21 [8242641.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4750-5 [8062274.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):281-91 [8658212.001]
  • [Cites] J Biol Chem. 1998 Sep 4;273(36):23046-54 [9722530.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):447-58 [15542429.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8688-93 [15574778.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3987-94 [15806169.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3886-95 [15856031.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):576-83 [15948711.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):156-69 [16012945.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6780-8 [16061660.001]
  • [Cites] Br J Cancer. 2005 Dec 12;93(12):1395-9 [16265349.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):57-61 [16397024.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):989-95 [16467114.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1467-79 [16518809.001]
  • [Cites] Tumour Biol. 2006;27(3):166-74 [16641550.001]
  • [Cites] Methods Enzymol. 2006;407:290-310 [16757333.001]
  • [Cites] Oncogene. 2006 Jun 29;25(28):3934-8 [16462760.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):32-8 [17013896.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11668-76 [17178861.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Cancer Sci. 2007 Jan;98(1):88-95 [17083569.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1254-60 [17408633.001]
  • [Cites] Int J Oncol. 2007 Jul;31(1):169-73 [17549418.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6203-11 [17404571.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • (PMID = 18310659.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; 0 / RASSF2 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2500213
  •  go-up   go-down


53. Li J, Hong M, Pan T: Clinical significance of VEGF-C and VEGFR-3 expression in non-small cell lung cancer. J Huazhong Univ Sci Technolog Med Sci; 2006;26(5):587-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of VEGF-C and VEGFR-3 expression in non-small cell lung cancer.
  • The relationship between vascular endothelial growth factor-C (VEGF-C)/vascular endothelial growth factor receptor 3 (VEGFR-3) expression and clinicopathologic features of the patients with non-small cell lung cancer (NSCLC) was investigated.
  • The results showed that VEGF-C and VEGFR-3 were highly expressed in cytoplasm and membrane in lung cancer tissues with the positive rate being 55.4 % and 52.3 % respectively, while there was no expression in the normal lung tissues.
  • The VEGFR-3 expression was closely related with lymph node metastasis (P<0.01) and TNM stage (P<0.05).
  • It is suggested that VEGFR-3 plays an important role in the lymphatic metastasis of NSCLC.
  • The interaction between VEGF-C and VEGFR-3 may be deeply involved in the mechanism of lung cancer metastasis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor Receptor-3 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2004 Oct;46(1):11-9 [15364128.001]
  • [Cites] J Pathol. 2001 Apr;193(4):450-7 [11276003.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):556-68 [11505400.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):309-13 [10390013.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2111-8 [8918404.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):93-7 [11437408.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):255-60 [11461086.001]
  • [Cites] Nat Med. 2001 Feb;7(2):199-205 [11175851.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):918-23 [11313181.001]
  • (PMID = 17219976.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


54. Sakurai T, Umemura T, Jinta E, Suzuma T, Yoshimura G, Shimizu S, Sakurai T: [Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2433-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report].
  • We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy.
  • FDG-PET scan revealed neck lymph node metastases from the breast cancer.
  • The recurrent nerve palsy was thus considered to have been caused by the lymph node metastases.
  • This resulted in a remarkable response after five months, with the recurrent nerve palsy completely disappearing at six months.
  • Oral anti-cancer treatments such as DMpC appear to have few side effects and might be an effective treatment option for recurrent breast cancer patients with triple negative disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Cyclophosphamide / therapeutic use. Floxuridine / therapeutic use. Medroxyprogesterone Acetate / therapeutic use. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Triple Negative Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098418.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 8N3DW7272P / Cyclophosphamide; C2QI4IOI2G / Medroxyprogesterone Acetate; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


55. Miccoli P, Materazzi G, Berti P: Minimally invasive thyroidectomy in the treatment of well differentiated thyroid cancers: indications and limits. Curr Opin Otolaryngol Head Neck Surg; 2010 Apr;18(2):114-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: Papillary carcinoma is the main indication for MIVAT, this cancer usually being found in normal glands of young women.
  • In contrast, for locally invasive carcinomas, lymph node metastasis or both, the procedure must be immediately converted to the conventional technique.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness. Neoplasm Staging. Video-Assisted Surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182356.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


56. Wang T, Hu K, Ren J, Zhu Q, Wu G, Peng G: Polymorphism of VEGF-2578C/A associated with the risk and aggressiveness of nasopharyngeal carcinoma in a Chinese population. Mol Biol Rep; 2010 Jan;37(1):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphism of VEGF-2578C/A associated with the risk and aggressiveness of nasopharyngeal carcinoma in a Chinese population.
  • In this report, we sought to investigate whether the VEGF-2578C/A polymorphism was associated with NPC in a Chinese population.
  • In contrast, NPC patients with the -2578CC genotype were shown higher tumor aggressiveness of large tumor size, poor differentiation and advanced stage as compared to the -2578A allele carriers.
  • No correlation was observed between the genotype or allele distribution and lymph node metastasis or family history of cancer.

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3647-53 [15897560.001]
  • [Cites] Mol Biol Rep. 2008 Mar;35(1):17-22 [17216542.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):395-9 [12118254.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R22 [16613616.001]
  • [Cites] Mol Biol Cell. 1992 Feb;3(2):211-20 [1550962.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):1147-55 [17287073.001]
  • [Cites] Hypertension. 1995 May;25(5):913-7 [7737726.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10972-7 [10995484.001]
  • [Cites] J Am Soc Nephrol. 2002 Jan;13(1):260-4 [11752046.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Circulation. 1996 Apr 15;93(8):1493-5 [8608615.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Diabetes. 2002 May;51(5):1635-9 [11978667.001]
  • [Cites] Int J Cancer. 1998 Jul 17;77(2):228-35 [9650558.001]
  • [Cites] Am J Ind Med. 2000 May;37(5):532-41 [10723047.001]
  • [Cites] Genet Test. 2008 Sep;12(3):345-9 [18627284.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):3-7 [1309307.001]
  • [Cites] J Endocrinol. 2007 Nov;195(2):265-70 [17951537.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):421-9 [12450728.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):293-8 [15541813.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5736-40 [11479209.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):812-6 [12591731.001]
  • [Cites] Eur J Cancer. 2008 Jul;44(11):1572-6 [18514506.001]
  • [Cites] J Pathol. 1991 Sep;165(1):17-24 [1659626.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Genes Immun. 2002 Jun;3(4):229-32 [12058259.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):18-32 [1372863.001]
  • [Cites] Clin Chim Acta. 2008 Sep;395(1-2):124-9 [18588866.001]
  • (PMID = 19340604.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


57. Gao X, Zhou T, Tang YJ, Lu X, Sun YH: Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy. Asian J Androl; 2009 Jan;11(1):127-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study is to evaluate the therapeutic effect of radical prostatectomy combined with preoperative neoadjuvant hormonal ablation therapy for prostate cancer (PCa).
  • A total of 31 patients received pelvic lymph node clearance, and the rate of positive lymph nodes was 12.9% (4/31).
  • There were significant differences in the positive surgical margins, seminal vesicle invasion and lymph node metastasis between the neoadjuvant therapy group (n = 12) and the radical prostatectomy group (n = 19, P < 0.01).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Nov;164(5):1465-72 [11025684.001]
  • [Cites] J Urol. 2001 Aug;166(2):500-6; discussion 506-7 [11458055.001]
  • [Cites] Urology. 2001 Aug;58(2 Suppl 1):71-7 [11502453.001]
  • [Cites] Urology. 2002 Sep;60(3 Suppl 1):45-51; discussion 51 [12231047.001]
  • [Cites] Urology. 2003 Dec 29;62 Suppl 1:46-54 [14747041.001]
  • [Cites] N Engl J Med. 1989 Aug 17;321(7):419-24 [2503724.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):11-8 [17208133.001]
  • [Cites] Cancer. 1993 Feb 1;71(3 Suppl):1031-8 [7679037.001]
  • [Cites] J Urol. 1993 Apr;149(4):779-82 [7681117.001]
  • [Cites] Eur Urol. 1993;24 Suppl 2:46-50 [7505231.001]
  • [Cites] J Urol. 1996 Jan;155(1):213-9 [7490838.001]
  • [Cites] J Urol. 1999 Jan;161(1):163-8 [10037390.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD006019 [17054269.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 1):331-7 [1635129.001]
  • (PMID = 19050694.001).
  • [ISSN] 1008-682X
  • [Journal-full-title] Asian journal of andrology
  • [ISO-abbreviation] Asian J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0F65R8P09N / Goserelin; 76W6J0943E / Flutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC3735205
  •  go-up   go-down


58. Chen DT, Chen JJ, Cheng G, Lin SH, Soong SJ: A two-stage binomial test approach of gene identification in oligonucleotide arrays. J Biopharm Stat; 2007;17(5):903-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a series of benchmark gene array datasets, we show the two-stage binomial test approach yielded a higher positive predictivity and a higher sensitivity than the conventional RMA, GCRMA, Dchip, and ANOVA approaches.
  • In data application, the two-stage binomial test identified a subset of genes strongly related to cell proliferation in the prolactin study, and a subset of genes associated with lymph node metastasis in the breast cancer dataset.
  • In the breast cancer dataset, the approach also identified one potential alternative splicing gene.
  • [MeSH-minor] Alternative Splicing. Binomial Distribution. Breast Neoplasms / epidemiology. Breast Neoplasms / genetics. Data Interpretation, Statistical. Female. Gene Expression / physiology. Humans. Lymphatic Metastasis / genetics. Oligonucleotide Probes. Predictive Value of Tests. Prolactin / biosynthesis. Prolactin / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885873.001).
  • [ISSN] 1054-3406
  • [Journal-full-title] Journal of biopharmaceutical statistics
  • [ISO-abbreviation] J Biopharm Stat
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA89019; United States / NCI NIH HHS / CA / 1U54 CA100949; United States / NCI NIH HHS / CA / 2P30 CA076292-09; United States / NCI NIH HHS / CA / 5P30 CA-13148; United States / NIDCD NIH HHS / DC / N01-DC-5-0008; United States / NIAID NIH HHS / AI / P30 AI 27767
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotide Probes; 0 / RNA, Messenger; 9002-62-4 / Prolactin
  •  go-up   go-down


59. Elsheikh MN, Rinaldo A, Ferlito A, Fagan JJ, Suárez C, Lowry J, Paleri V, Khafif A, Olofsson J: Elective supraomohyoid neck dissection for oral cavity squamous cell carcinoma: is dissection of sublevel IIB necessary? Oral Oncol; 2008 Mar;44(3):216-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nerve dysfunction is usually attributed to excessive nerve traction or devascularization during clearance of the lymph nodes posterior and superior to the SAN (sublevel IIB).
  • This review article discusses whether preserving sublevel IIB lymph nodes is justified in elective SOHND for patients with squamous cell carcinoma (SCC) of the oral cavity.
  • Only two studies have prospectively investigated the incidence of lymph node metastasis in patients with clinically N0 SCC of the oral cavity.
  • Data from these two prospective pathologic and molecular analyses of neck dissection specimens, including 122 patients with N0 oral cancer, revealed 7.3% with positive neck nodes at sublevel IIB for oral cancer in general, and 12% for tongue cancer in particular.
  • [MeSH-minor] Accessory Nerve Injuries. Humans. Iatrogenic Disease. Neoplasm Recurrence, Local. Neoplasm Staging. Risk. Treatment Outcome


60. Yamagishi D, Kawamura S, Tei M, Habara K, Sumi Y, Shimada E, Okumura S: [A case of non-curatively resected gastric cancer successfully treated over 3 years with biweekly paclitaxel therapy]. Gan To Kagaku Ryoho; 2006 Jun;33(6):803-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-curatively resected gastric cancer successfully treated over 3 years with biweekly paclitaxel therapy].
  • We report a case of non-curatively resected gastric cancer successfully treated over 3 years with biweekly administration of paclitaxel.
  • A 69-year-old man underwent non-curative resection with distal gastrectomy for advanced gastric cancer with remarkable lymph node metastasis on June 10, 2002.
  • The metastatic lymph node (No. 8 a, 8 p and 12 a) linked up with the retroperitoneal node, making resection impossible.
  • We believe that, in paclitaxel therapy for advanced gastric cancer, it is important for long-term survival to continue it perseveringly by dose reduction or change of schedule, when major adverse reactions are seen.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Lymph Nodes / pathology. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Gastrectomy. Humans. Lymphatic Metastasis. Male. Neutropenia / chemically induced. Survivors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770101.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


61. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, Wang Y: Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res; 2005 Oct 15;11(20):7234-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel genes associated with malignant melanoma but not benign melanocytic lesions.
  • PURPOSE: Cutaneous melanoma is a common, aggressive cancer with increasing incidence.
  • The identification of melanoma-specific deregulated genes could provide molecular markers for lymph node staging assays and further insight into melanoma tumorigenesis.
  • Novel genes associated with malignant melanoma were identified.
  • Differential gene expression of two melanoma-specific genes, PLAB and L1CAM, were tested by a one-step quantitative reverse transcription-PCR assay on primary malignant melanoma, benign nevi, and normal skin samples, as well as on malignant melanoma lymph node metastasis and melanoma-free lymph nodes.
  • CONCLUSION: Our study systematically identified novel melanoma-specific genes and showed the feasibility of using a combination of PLAB and L1CAM in a reverse transcription-PCR assay to differentiate clinically relevant samples containing benign or malignant melanocytes.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / genetics. Cluster Analysis. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243793.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


62. Moon HG, Jeong SH, Ju YT, Jeong CY, Lee JS, Lee YJ, Hong SC, Choi SK, Ha WS, Park ST, Jung EJ: Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications. Cancer Res Treat; 2010 Sep;42(3):151-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications.
  • PURPOSE: Recent research has identified many genes and proteins that play specific roles in the process of systemic metastasis in various types of cancer.
  • Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to inhibit metastasis in human bladder cancer, but its role in breast cancer is controversial.
  • MATERIALS AND METHODS: We examined the regulation and clinical significance of RhoGDI2 in Korean breast cancer patients by using proteomic approaches.
  • RESULTS: By using a proteomic approach, we observed an increased expression of RhoGDI2 in human breast cancer tissues when compared to that of the normal breast tissues, and we validated its up-regulation in an independent cohort of 8 breast cancer patients.
  • The clinical implication of a RhoGDI2 expression was investigated in 57 breast cancer patients by performing immunohistochemistry.
  • RhoGDI2 did not show a significant association with the tumor size, lymph node metastasis, the histologic grade or the hormone receptor status.
  • However, the patients with RhoGDI2-expressing tumors had significantly shorter disease-free survival (p=0.043; hazard ratio, 3.87) and distant metastasis-free survival (p=0.039; hazard ratio, 5.15).
  • The pro-metastatic nature of RhoGDI2 shown in our study may indicate its organ-specific role in cancer metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948920.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2953778
  • [Keywords] NOTNLM ; Breast neoplasms / Neoplasm metastasis / Prognosis / Proteomics / RhoGDI2 protein
  •  go-up   go-down


63. Bournaud C, Charrié A, Nozières C, Chikh K, Lapras V, Denier ML, Paulin C, Decaussin-Petrucci M, Peix JL, Lifante JC, Cornu C, Giraud C, Orgiazzi J, Borson-Chazot F: Thyroglobulin measurement in fine-needle aspirates of lymph nodes in patients with differentiated thyroid cancer: a simple definition of the threshold value, with emphasis on potential pitfalls of the method. Clin Chem Lab Med; 2010 Aug;48(8):1171-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroglobulin measurement in fine-needle aspirates of lymph nodes in patients with differentiated thyroid cancer: a simple definition of the threshold value, with emphasis on potential pitfalls of the method.
  • BACKGROUND: Thyroglobulin measurements in fine-needle aspirate (FNA-Tg) is an accurate method for the diagnosis of lymph node metastasis in differentiated thyroid carcinoma.
  • METHODS: Ultrasound-guided fine-needle aspiration-cytology (FNA-C) and FNA-Tg were performed on suspicious lymph nodes in 114 consecutive patients with thyroid cancer prior to thyroidectomy (n=13) or during follow-up (n=93), and in 16 control subjects.
  • CONCLUSIONS: A unique threshold of 0.93 ng/p gives high sensitivity and specificity, even in non-thyroidectomized patients.
  • However, since false negative results may be observed in poorly differentiated thyroid cancer, FNA-C should remain combined to FNA-Tg.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441483.001).
  • [ISSN] 1437-4331
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


64. Li T, Zhou J, Deng Z, Fu C, Jiang H, Gao Z, Wang J, Ren H, Wang P: [Expression of FGF-2 and osteopontin in non-small cell lung cancer]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Nov;34(11):1114-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of FGF-2 and osteopontin in non-small cell lung cancer].
  • OBJECTIVE: To investigate the expression of fibroblast growth factor-2 (FGF-2) and osteopontin (OPN) in non-small cell lung cancer (NSCLC) tissues and analyze the correlation between FGF-2 and OPN.
  • The expression of FGF-2 and OPN was closely related to TNM stages and the lymph node metastasis (all Ps<0.01), but not to histological types, sex, and age of NSCLC patients (all Ps>0.05).A positive correlation was found between the expression of FGF-2 and OPN in NSCLC (r=0.552,P<0.01).
  • CONCLUSION: The overexpression of FGF-2 and OPN is related to the metastasis and invasion of NSCLC.FGF-2 may promote the metastasis and invasion of NSCLC depending on the upregulation of OPN expression.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Fibroblast Growth Factor 2 / metabolism. Lung Neoplasms / metabolism. Osteopontin / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952401.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SPP1 protein, human; 103107-01-3 / Fibroblast Growth Factor 2; 106441-73-0 / Osteopontin
  •  go-up   go-down


65. Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D, Coukos G, Zhang L, Huang Q: KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol; 2009 Nov;11(11):1297-304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer.
  • Metastasis is a complex multistep process, which requires the concerted action of many genes and is the primary cause of cancer death.
  • Both pathways that regulate metastasis enhancement and those that regulate its suppression contribute to the tumour dissemination process.
  • To identify new metastasis suppressors, we set up a forward genetic screen in a mouse model.
  • We transduced a genome-wide RNA interference (RNAi) library into the non-metastatic 168FARN breast cancer cell line and orthotopically transplanted the cells into mouse mammary fat pads.
  • Conversely, we demonstrate that ectopic expression of KLF17 in a highly metastatic 4T1 breast cancer cell line inhibits the ability of cells to metastasize from the mammary fat pad to the lung.
  • We also show that suppression of KLF17 expression promotes breast cancer cell invasion and epithelial-mesenchymal transition (EMT), and that KLF17 protein functions by directly binding to the promoter region of Id1 (which encodes a key metastasis regulator in breast cancer) to inhibit its transcription.
  • Finally, we demonstrate that KLF17 expression is significantly downregulated in primary human breast cancer samples and that the combined expression pattern of KLF17 and Id1 can serve as a potential biomarker for lymph node metastasis in breast cancer.


66. Kato H, Kimura H, Nakajima M, Sakai M, Sano A, Tanaka N, Inose T, Faried A, Saito K, Ieta K, Sohda M, Fukai Y, Miyazaki T, Masuda N, Fukuchi M, Ojima H, Tsukada K, Oriuchi N, Endo K, Kuwano H: The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer. Oncol Rep; 2008 Oct;20(4):857-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer.
  • The purpose of the present study was to assess the contribution of simultaneous functional/anatomical imaging using integrated 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT), compared with PET alone for the evaluation of initial lymph node staging in esophageal cancer.
  • Comparisons between CT, PET and PET/CT in detecting lymph node metastasis by each region showed that PET/CT had a higher sensitivity in lower thoracic regions than PET and CT (p<0.05 vs. CT and PET).
  • Lymph node staging (N0 vs. N1) was not significantly different, but staging per lymph nodal group was significantly better with PET/CT.
  • Integrated PET/CT imaging with co-registration of anatomic and functional imaging data is useful in the initial lymph node staging of patients with operable esophageal cancer compared with PET alone.
  • [MeSH-major] Esophageal Neoplasms / pathology. Lymph Nodes / pathology. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging


67. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G, Spizzo G: High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer; 2008 Oct 21;99(8):1290-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of TROP2 correlates with poor prognosis in pancreatic cancer.
  • Pancreatic cancer is one of the most devastating human malignancies.
  • The human trophoblast cell-surface antigen, TROP2, was found to be strongly expressed in a variety of human epithelial cancers, correlating with aggressiveness and poor prognosis.
  • Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model.
  • TROP2 overexpression was observed in 109 (55%) of 197 pancreatic cancer patients and was significantly associated with decreased overall survival (P<0.01).
  • By univariate analysis, TROP2 overexpression was found to correlate with the presence of lymph node metastasis (P=0.04) and tumour grade (P=0.01).
  • These findings suggest for the first time that TROP2 could be a novel prognostic biomarker for pancreatic cancer.
  • Targeting TROP2 might be a useful treatment approach for patients with pancreatic cancer overexpressing this cell-surface marker.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2006;6:165 [16796747.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3079s-3087s [10541347.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):280-5 [18281513.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):209-20 [11391791.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1239-49 [11943709.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):111-8 [12517786.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):489-94 [14965442.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):173-82 [14999147.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3131-6 [15131054.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):1029-35 [15386348.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jan;81(1):224-8 [6364135.001]
  • [Cites] Mol Cell Biol. 1993 Mar;13(3):1507-15 [8382772.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):938-46 [8253531.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):988-95 [7504658.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):437-46 [8163559.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):472-9 [7635574.001]
  • [Cites] Int J Cancer. 1995 Sep 4;62(5):610-8 [7665234.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5857s-5863s [7493360.001]
  • [Cites] Science. 1997 May 23;276(5316):1268-72 [9157888.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1788-94 [9586892.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):671-6 [9610724.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):478-83 [9716030.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7555-65 [15569986.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3057-63 [16707602.001]
  • [Cites] Dev Dyn. 2006 Jun;235(6):1578-88 [16552761.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):186-91 [18084248.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):1981-2 [11130529.001]
  • (PMID = 18813308.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 090532; Austria / Austrian Science Fund FWF / / W 1101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / TACSTD2 protein, human
  • [Other-IDs] NLM/ PMC2570520
  •  go-up   go-down


68. Togawa O, Kawabe T, Isayama H, Nakai Y, Sasaki T, Arizumi T, Matsubara S, Ito Y, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Yoshida H, Omata M: Management of occluded uncovered metallic stents in patients with malignant distal biliary obstructions using covered metallic stents. J Clin Gastroenterol; 2008 May-Jun;42(5):546-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of occluded uncovered metallic stents in patients with malignant distal biliary obstructions using covered metallic stents.
  • BACKGROUND: Self-expandable metallic stents (EMSs) have been widely used for the palliative treatment of unresectable malignant biliary obstructions, but EMSs are often occluded owing to tumor ingrowth via the wire mesh.
  • We evaluated the efficacy of a covered EMS as a second endoprosthesis in patients with an occluded EMS.
  • The patients suffered from the following: pancreatic cancer in 18, bile duct cancer in 11, gallbladder cancer in 5, lymph node metastasis in 4, and papillary cancer in 2.
  • Of these, 26, 7, and 7 were treated with a covered EMS, an uncovered EMS, and a plastic stent (PS), respectively.
  • CONCLUSION: Insertion of a covered EMS is an effective and safe treatment for an occluded uncovered EMS.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / complications. Bile Duct Neoplasms / diagnosis. Duodenal Neoplasms / complications. Duodenal Neoplasms / diagnosis. Female. Follow-Up Studies. Gallbladder Neoplasms / complications. Gallbladder Neoplasms / diagnosis. Humans. Japan / epidemiology. Male. Middle Aged. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / diagnosis. Prosthesis Failure. Reoperation. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344884.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coated Materials, Biocompatible; 0 / Metals
  •  go-up   go-down


69. Yonekawa H, Sugitani I, Fujimoto Y, Arai M, Yamamoto N: A family of multiple endocrine neoplasia type 2A (MEN 2A) with Cys630Tyr RET germline mutation: report of a case. Endocr J; 2007 Aug;54(4):531-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A family of multiple endocrine neoplasia type 2A (MEN 2A) with Cys630Tyr RET germline mutation: report of a case.
  • Since the majority of multiple endocrine neoplasia type 2A (MEN 2A) patients have missense mutations at codon 634 and those with the Cys630 RET genotype mutations are extremely rare, limited clinical information is available about this rare type.
  • No lymph node metastasis was identified.
  • Computed tomography scans and laboratory examination of blood have shown no evidence of tumor recurrence and no abnormality of parathyroid function during the 4 years after surgery.
  • [MeSH-major] Germ-Line Mutation. Multiple Endocrine Neoplasia Type 2a / genetics. Proto-Oncogene Proteins c-ret / genetics

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • Genetic Alliance. consumer health - Multiple endocrine neoplasia type 2A.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527003.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  •  go-up   go-down


70. Papp Z, Csapó Z, Hupuczi P, Mayer A: Nerve-sparing radical hysterectomy for stage IA2-IIB cervical cancer: 5-year survival of 501 consecutive cases. Eur J Gynaecol Oncol; 2006;27(6):553-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nerve-sparing radical hysterectomy for stage IA2-IIB cervical cancer: 5-year survival of 501 consecutive cases.
  • OBJECTIVE: The purpose of this study was to assess the 5-year survival and morbidity in cases with radical hysterectomy and pelvic lymphadenectomy with pre- and postoperative irradiation performed to treat Stage IA2-IIB cervical cancer.
  • METHODS: During a 10(1/2)-year period between July 1990 and December 2000, 501 consecutive radical hysterectomies with bilateral pelvic lymphadenectomy were performed by the same gynecological surgeon in Stage IA2, IB, IIA and IIB cervical cancer.
  • The respective 5-year survival rates for patients without or with lymph node metastasis were 94.5% and 33.3% in Stage IB2, 81.7% and 48.7% in Stage IIA and 70.2% and 36.5% in Stage IIB, respectively.
  • CONCLUSIONS: Nerve-sparing radical hysterectomy with pelvic lymph node dissection and pre- and postoperative irradiation remains the treatment of choice for most patients with early-stage and even Stage IIB cervical cancer.
  • The radicalism and extent of lymph node dissection and parametrial resection should be individualized and tailored to tumor- and patient-related risk factors.
  • [MeSH-major] Hypogastric Plexus / injuries. Hysterectomy / methods. Lymph Node Excision / methods. Pelvic Floor / innervation. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Longitudinal Studies. Middle Aged. Neoplasm Staging. Survival Analysis. Uterus / blood supply


71. Akyürek N, Memiş L, Ekinci O, Köktürk N, Oztürk C: Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch; 2006 Aug;449(2):164-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in pre-invasive lesions and non-small cell lung carcinoma.
  • The aim of this immunohistochemical study was to investigate the role of survivin in the early steps of lung carcinogenesis and non-small cell lung carcinomas (NSCLC), and its relationship with expression of p53 protein, a tumor suppressor gene involved in cell cycle control.
  • In the normal bronchial epithelium, low-grade atypical adenomatous hyperplasia (AAH) and non-neoplastic lung parenchyma adjacent to tumor, survivin was found completely negative.
  • Expression of survivin was detected in the areas of squamous metaplasia and dysplasia as well as high-grade AAH lesions adjacent to tumor.
  • Survivin expression was significantly correlated with lymph node metastasis (p=0.02).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / chemistry. Lung Neoplasms / chemistry. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Folia Histochem Cytobiol. 2005;43(4):237-42 [16382892.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):712-9 [14608897.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7183-90 [15492230.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):353-61 [15936846.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):299-304 [15541814.001]
  • [Cites] Semin Cancer Biol. 2004 Aug;14(4):231-43 [15219616.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2195-203 [12796386.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):44-9 [15163019.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):554-60 [12384799.001]
  • [Cites] Chin Med Sci J. 2005 Sep;20(3):214-6 [16261898.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2613-22 [11965534.001]
  • [Cites] J Dent Res. 2003 Nov;82(11):923-8 [14578507.001]
  • [Cites] Am J Clin Oncol. 2004 Aug;27(4):425-8 [15289739.001]
  • [Cites] Eur Respir J Suppl. 2003 Jan;39:36s-44s [12572700.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2100-4 [10561264.001]
  • [Cites] Lab Invest. 1999 Sep;79(9):1121-6 [10496530.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1685-92 [15742356.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2026-32 [11391581.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):835-8 [12066218.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):537-40 [15266313.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):738-44 [12090422.001]
  • [Cites] J Pathol. 2003 Aug;200(5):620-6 [12898598.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1215-21 [16211215.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1355-67 [10764334.001]
  • [Cites] Chest. 2002 Sep;122(3):1037-57 [12226051.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):509-12 [15578717.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1654-60 [15520067.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • [Cites] Lung Cancer. 2005 May;48(2):281-9 [15829330.001]
  • (PMID = 16810543.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


72. Yan C, Zhu ZG, Zhan WW, Yan M, Yu YY, Liu BY, Yin HR, Lin YZ: [Value of transabdominal ultrasonography in preoperative assessment of gastric carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Mar;8(2):121-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the value of transabdominal ultrasonography (TAUS) in preoperative assessment of TNM stage and tumor angiogenesis for patients with gastric carcinoma.
  • METHODS: Sixty- four patients with gastric carcinoma preoperatively underwent TAUS, in whom transabdominal color Doppler ultrasonography was used for measuring color Doppler vascularity index (CDVI) of each tumor in 37 cases and microvessel density (MVD) was evaluated by using immunohistochemical staining of surgical specimens with anti- CD34 antibody.
  • The diagnostic accuracy rate was 63.3% for lymph node status of gastric carcinoma.
  • The diagnostic sensitivity and specificity for lymph node metastasis was 37.9% and 100% respectively.
  • The diagnostic sensitivity and specificity for determining distant metastases was 58.3% and 100% respectively.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Microvessels. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / ultrasonography

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155820.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


73. Yamazawa K, Hirashiki K, Usui H, Mitsuhashi A, Matsui H, Sekiya S: Discordance between serum level and tissue immunohistochemical staining of CA125 in endometrioid adenocarcinoma of the uterine corpus. Int J Gynecol Pathol; 2005 Jul;24(3):254-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was designed to correlate tissue expression of CA125 with the corresponding serum value in endometrial cancer.
  • Fifteen patients with elevated serum CA125 levels statistically differed from the remaining 37 patients with normal serum CA125 level with respect to International Federation of Gynecology and Obstetrics (FIGO) stage (p = 0.027) and lymph node metastasis (p = 0.024), and tended to have positive washing cytology (p = 0.052).
  • In multivariate analysis, elevated serum CA125 significantly correlated only with FIGO stage III, but not with tumor size or CA125 tissue staining.
  • Intrauterine tumor may not be the main source of serum CA125 in endometrial cancer, and elevated serum level is closely related to the presence of disseminated cancer cells in the peritoneal cavity.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CA-125 Antigen / metabolism. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968201.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


74. Mizuno T, Ishizaki Y, Ogura K, Yoshimoto J, Kawasaki S: Clinical significance of immunohistochemically detectable lymph node metastasis in adenocarcinoma of the ampulla of Vater. Br J Surg; 2006 Feb;93(2):221-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of immunohistochemically detectable lymph node metastasis in adenocarcinoma of the ampulla of Vater.
  • BACKGROUND: The aim of this study was to assess the impact of immunohistochemically identified lymph node metastasis on survival in patients with carcinoma of the ampulla of Vater.
  • METHODS: Three hundred and twenty-six regional lymph nodes dissected from pancreatoduodenectomy specimens from 25 patients with ampulla of Vater carcinoma were immunostained with anticytokeratin antibody (CAM 5.2).
  • The clinicopathological significance of immunohistochemically detectable lymph node metastasis was evaluated and compared with that of other potential prognostic factors.
  • RESULTS: The frequency of lymph node involvement in relation to the total number of dissected lymph nodes increased from 5.5 per cent (18 of 326) using haematoxylin and eosin staining to 9.5 per cent (31 of 326) using cytokeratin immunostaining (P < 0.001).
  • Lymph node involvement was revealed by haematoxylin and eosin staining in eight of 25 patients and by cytokeratin immunostaining in 11 of 25 patients (P = 0.006).
  • Absence of immunohistochemically detectable lymph node metastasis was identified as an independent predictor of improved postoperative survival.
  • CONCLUSION: Immunostaining of dissected lymph nodes adds additional information to data obtained by conventional haematoxylin and eosin staining when determining the prognosis of patients with carcinoma of the ampulla of Vater.
  • [MeSH-major] Adenocarcinoma / secondary. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 16363020.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Shiono S, Kawamura M, Sato T, Okumura S, Nakajima J, Yoshino I, Ikeda N, Horio H, Akiyama H, Kobayashi K, Metastatic Lung Tumor Study Group of Japan: Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg; 2009 Sep;88(3):856-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas.
  • BACKGROUND: The lung is the major organ for distant metastasis from head and neck cancers, and pulmonary metastasectomy is indicated for selected cases.
  • The efficacy of surgical treatment for pulmonary metastatic lesions from head and neck cancers has not been thoroughly examined.
  • METHODS: The database developed by the Metastatic Lung Tumor Study Group of Japan was retrospectively reviewed.
  • Between November 1980 and September 2006, 237 patients underwent resection of pulmonary metastases from primary head and neck cancers.
  • After excluding nonsquamous cell carcinomas, 114 cases were analyzed, and the survival and prognostic factors for pulmonary metastasectomy for metastases from head and neck cancers were determined.
  • As determined by univariate analysis, poor prognostic factors were oral cavity cancers, lymph node metastasis, a disease-free interval of 24 months or less, and incomplete resection.
  • Multivariate analysis revealed that poor prognostic factors were being male, having oral cavity cancers, lymph node metastasis, and incomplete resection.
  • Survival of male patients with oral cavity cancer that metastasized was significantly reduced (p < 0.001).
  • CONCLUSIONS: Male sex, oral cavity cancers, lymph node metastasis, and incomplete resection were poor prognostic factors for pulmonary metastases, but there is the potential for a good surgical outcome in carefully selected patients.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Otorhinolaryngologic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2009 Sep;88(3):861 [19699912.001]
  • (PMID = 19699911.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


76. Horiguchi J, Koibuchi Y, Yoshida T, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, Iino Y, Morishita Y: Significance of local recurrence as a prognostic factor in the treatment of breast cancer. Anticancer Res; 2006 Jan-Feb;26(1B):569-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of local recurrence as a prognostic factor in the treatment of breast cancer.
  • The aim of this study was to evaluate both the risk factors of local recurrence and the prognostic significance of local recurrence in relation to surgical treatment and/or radiation therapy of breast cancer.
  • A total of 1574 primary breast cancer patients, undergoing surgical treatment and/or radiation therapy between 1980 and 2001, were included in this study.
  • Independent prognostic factors in local recurrence were lymph node metastasis in the radical mastectomy group, and surgical margin in the subcutaneous mastectomy group and the breast-conserving therapy group.
  • Independent prognostic factors in overall survival were local recurrence, lymph node metastasis and estrogen receptor status in the radical mastectomy group, and lymph node metastasis and estrogen receptor status in the breast-conserving therapy group.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739322.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


77. Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA: Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res; 2009 Jan 1;69(1):349-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
  • Several preclinical and clinical studies have shown a positive correlation between the incidence of lymph node metastasis and secretion of the lymphatic growth factor vascular endothelial growth factor-C (VEGF-C) by tumor cells, suggesting tumor lymphangiogenesis as an escape mechanism.
  • However, recent evidence has shown VEGF receptor-3 (VEGFR-3) expression on tumor cells and autocrine signaling, which increase metastatic potential.
  • Furthermore, there is growing evidence implicating lymphatic-homing chemokine receptors, particularly C-C chemokine receptor 7 (CCR7), in lymph node metastasis.
  • We report here that expressions of VEGF-C and CCR7 by tumor cells act synergistically to promote their invasion toward lymphatics.
  • First, VEGF-C acts to increase lymphatic secretion of CCL21, which in turn drives CCR7-dependent tumor chemoinvasion toward lymphatics.
  • Second, VEGF-C acts in an autocrine fashion to increase tumor invasiveness by increasing the proteolytic activity and motility of tumor cells in a three-dimensional matrix.
  • Taken together, these results bridge the prometastatic functions of CCR7 and VEGF-C in tumors and show that, beyond lymphangiogenesis, VEGF-C promotes tumor invasion toward lymphatics by both autocrine and CCR7-dependent paracrine signaling mechanisms, which may be a significant cause of lymph node metastasis.
  • [MeSH-minor] Cell Line, Tumor. Cell Movement / physiology. Chemokine CCL21 / secretion. Humans. Lymphatic Metastasis. Lymphatic Vessels / secretion. Neoplasm Invasiveness. Receptor Cross-Talk. Signal Transduction. Vascular Endothelial Growth Factor Receptor-3 / biosynthesis. Vascular Endothelial Growth Factor Receptor-3 / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19118020.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL21 protein, human; 0 / Chemokine CCL21; 0 / Receptors, CCR7; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


78. Silva TA, Ribeiro FL, Oliveira-Neto HH, Watanabe S, Alencar Rde C, Fukada SY, Cunha FQ, Leles CR, Mendonça EF, Batista AC: Dual role of CCL3/CCR1 in oral squamous cell carcinoma: implications in tumor metastasis and local host defense. Oncol Rep; 2007 Nov;18(5):1107-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual role of CCL3/CCR1 in oral squamous cell carcinoma: implications in tumor metastasis and local host defense.
  • Chemokines are small chemotactic cytokines that can induce the migration of leukocytes, activate inflammatory/immune responses and have recently been implicated in the regulation of tumor growth and organ-specific spread.
  • In this setting, the macrophage inflammatory protein-1alpha (CCL3) chemokine displays a diversity of roles that may contribute to the directional migration of squamous cells into cervical lymph nodes or to the defense against tumor initiation and progression.
  • In addition, we investigated the immunoexpression of these molecules in neoplastic cells (parenchyma), inflammatory/immune cells (stroma) in primary OSCC and in metastatic and non-metastatic lymph node tissues.
  • The percentages of CCL3+ and CCR1+ cells were observed to be similar in parenchyma and stroma in the OSCC without lymph node metastasis when compared with OSCC with lymph node metastasis (P>0.05).
  • However, we observed the density of CCL3+ nodal cells to be significantly higher in metastatic lymph nodes when compared with non-metastatic lymph nodes in the same patients (P<0.05).
  • Our findings suggest that the CCL3/CCR1 axis may have a role in the spread of tumoral cells to the lymph nodes and also in the local host defense against the tumor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914560.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CCR1 protein, human; 0 / Chemokine CCL3; 0 / RNA, Messenger; 0 / Receptors, CCR1
  •  go-up   go-down


79. O'Donnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, O'Malley B, Cheng Y, Putt M, Feldman M, Ziober B, Muschel RJ: Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene; 2005 Feb 10;24(7):1244-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity.
  • Metastasis via the lymphatics is a major risk factor in squamous cell carcinoma of the oral cavity (OSCC).
  • We sought to determine whether the presence of metastasis in the regional lymph node could be predicted by a gene expression signature of the primary tumor.
  • Metastatic primary tumors could be differentiated from nonmetastatic primary tumors by a signature gene set of 116 genes.
  • This signature gene set correctly predicted the four independent patients as well as associating five lymph node metastases from the original patient set with the metastatic primary tumor group.
  • We concluded that lymph node metastasis could be predicted by gene expression profiles of primary oral cavity squamous cell carcinomas.
  • The presence of a gene expression signature for lymph node metastasis indicates that clinical testing to assess risk for lymph node metastasis should be possible.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Gene Expression Profiling. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Down-Regulation / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Receptors, CXCR4 / genetics. Up-Regulation / genetics


80. Baloglu A, Bezircioglu I, Cetinkaya B, Yavuzcan A: Primary malignant melanoma of the vagina. Arch Gynecol Obstet; 2009 Nov;280(5):819-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the vagina.
  • BACKGROUND: Primary vaginal melanoma is a rare, highly malignant, and poor prognostic disease.
  • CASE: The 51-year-old patient with diagnosis of vaginal malignant melanoma was referred to our clinic.
  • Paraaortic lymph node metastasis was seen on the ninth month after total vaginectomy and the metastatic lymph nodes were excised.
  • The patient is alive and disease-free at 18th month of the diagnosis of the disease.
  • CONCLUSION: The impact of therapy on outcome of primary vaginal malign melanomas is poorly understood.
  • Because of the low rate of lymph node metastasis, elective pelvic lymph node dissection is not mandatory.
  • We presented a case of FIGO stage I primary vaginal malignant melanoma, which metastasized to the paraaortic lymph nodes 9 months after the primary operation.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Interferon-alpha / administration & dosage. Lymphatic Metastasis. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242707.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interferon-alpha; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


81. Xi L, Coello MC, Litle VR, Raja S, Gooding WE, Yousem SA, El-Hefnawy T, Landreneau RJ, Luketich JD, Godfrey TE: A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res; 2006 Apr 15;12(8):2484-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients.
  • Occult lymph node metastasis (micrometastasis) is a good prognostic indicator in non-small cell lung cancer (NSCLC) and could be used to direct adjuvant chemotherapy in stage I patients.
  • This study was designed to evaluate molecular markers for detection of occult lymph node metastasis in NSCLC, define the best marker or marker combination to distinguish positive from benign lymph nodes, and evaluate these markers in lymph nodes from pathologically node-negative (pN(0)) NSCLC patients.
  • Potential markers were identified through literature and database searches and all markers were analyzed by quantitative reverse transcription-PCR in a primary screen of six NSCLC specimens and 10 benign nodes.
  • Selected markers were further evaluated on 21 primary NSCLC specimens, 21 positive nodes, and 21 benign nodes, and the best individual markers and combinations were identified.
  • A combination of three markers was further validated on an independent set of 32 benign lymph nodes, 38 histologically positive lymph nodes, and 462 lymph nodes from 68 pN(0) NSCLC patients.
  • A combination of three markers (SFTPB, TACSTD1, and PVA) was identified that provided perfect classification of benign and positive nodes in all sample sets.
  • PVA and SFTPB are particularly powerful in tumors of squamous and adenocarcinoma histologies, respectively, whereas TACSTD1 is a good general marker for NSCLC metastasis.
  • The combination of these genes identified 32 of 462 (7%) lymph nodes from 20 of 68 (29%) patients as potentially positive for occult metastasis.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):6-15 [10631132.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):389-98 [16495705.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):84-91 [11272893.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):39-46 [11249047.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] J Pathol. 2001 Jul;194(3):298-302 [11439361.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491 [11882819.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Clin Chem. 2003 Feb;49(2):312-5 [12560358.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):611-8 [12845661.001]
  • [Cites] Am J Surg. 2003 Oct;186(4):324-9 [14553843.001]
  • [Cites] Clin Lung Cancer. 2004 Jan;5(4):214-25 [14967073.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2671-80 [15226334.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3417-20 [7542169.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4283-6 [7671236.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Oct;114(4):535-43 [9338638.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] JAMA. 1998 Oct 28;280(16):1410-5 [9801000.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):19-24 [10458213.001]
  • [Cites] Lancet. 1999 Sep 11;354(9182):896-900 [10489948.001]
  • [Cites] Chest. 2005 Feb;127(2):430-7 [15705978.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1099-109 [15709177.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2147-56 [15781625.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5017s-5021s [16000606.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s [16000607.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):429-35 [10646900.001]
  • (PMID = 16638856.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA094059-04; United States / NCI NIH HHS / CA / R01 CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059; United States / NCI NIH HHS / CA / CA094059-03; United States / NCI NIH HHS / CA / R01 CA094059-01; United States / NCI NIH HHS / CA / R01 CA090665; United States / NCI NIH HHS / CA / R01 CA094059-03; United States / NCI NIH HHS / CA / R01CA90665; United States / NCI NIH HHS / CA / CA094059-02; United States / NCI NIH HHS / CA / CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059-02; United States / NCI NIH HHS / CA / R01 CA094059-04; United States / NCI NIH HHS / CA / CA094059-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / DSG3 protein, human; 0 / Desmoglein 3; 0 / EPCAM protein, human; 0 / Pulmonary Surfactant-Associated Protein B
  • [Other-IDs] NLM/ NIHMS24707; NLM/ PMC1933488
  •  go-up   go-down


82. Inagaki Y, Tang W, Xu HL, Guo Q, Mafune K, Konishi T, Nakata M, Sugawara Y, Kokudo N: Localization of N-myc downstream-regulated gene 1 in gastric cancer tissue. Dig Liver Dis; 2009 Feb;41(2):96-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of N-myc downstream-regulated gene 1 in gastric cancer tissue.
  • BACKGROUND AND AIM: N-myc downstream-regulated gene 1 is detected in normal tissue but is down-regulated in cancer tissue.
  • This study sought to investigate the clinicopathological significance of N-myc downstream-regulated gene 1 and p53 expression in gastric cancer tissue.
  • PATIENTS AND METHODS: Immunohistochemical detection of N-myc downstream-regulated gene 1 and p53 was performed with tissue samples from 96 cases of gastric cancer, and the relationship between expression profiles of proteins and clinicopathological characteristics was statistically analysed.
  • RESULTS: Positive staining of N-myc downstream-regulated gene 1 was observed in the cytoplasm (22 of 96 cases, 22.9%) and/or nucleus (29 of 96 cases, 30.2%) of cancer cells.
  • The nuclear localization of N-myc downstream-regulated gene 1 was frequently observed in the region of cancerous invasion and was significantly related to lymph node metastasis.
  • In addition, accumulation of p53 protein in the nucleus of cancer cells significantly coincided with the nuclear localization of N-myc downstream-regulated gene 1.
  • CONCLUSIONS: Localization of N-myc downstream-regulated gene 1 and its significant correlation with p53 expression may play an important role in cancer progression.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602353.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


83. Lai JF, Kim S, Li C, Oh SJ, Hyung WJ, Choi WH, Choi SH, Wang LB, Noh SH: Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Oncol; 2008 May;15(5):1464-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, in regard to T4 invasion, N3 lymph node metastasis, and TNM stage IV, the characteristics of the tumors of young patients were similar to those of middle-aged and elderly patients.
  • Multivariate analysis indicated that age was an independent prognostic factor (as well as gender, operation type, depth of invasion, and lymph node status).
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Cell Differentiation. Female. Humans. Incidence. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340495.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Wind J, ten Kate FJ, Kiewiet JJ, Lagarde SM, Slors JF, van Lanschot JJ, Bemelman WA: The prognostic significance of extracapsular lymph node involvement in node positive patients with colonic cancer. Eur J Surg Oncol; 2008 Apr;34(4):390-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of extracapsular lymph node involvement in node positive patients with colonic cancer.
  • AIMS: In colonic cancer the prognostic significance of extracapsular lymph node involvement (LNI) is not established and is therefore the objective of this study.
  • METHODS: Between January 1994 and May 2005, all patients who underwent resection for primary colonic cancer with lymph node metastasis were reviewed.
  • All resected lymph nodes were re-examined to assess extracapsular LNI.
  • Univariate analysis revealed that pN-stage (5-year DFS pN1 vs. pN2: 65% vs. 14%, p<0.001), extracapsular LNI (5-year DFS intracapsular LNI vs. extracapsular LNI: 69% vs. 41%, p=0.003), and lymph node ratio (5-year DFS <0.176 vs. > or =0.176: 67% vs. 42%, p=0.023) were significant prognostic indicators.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614246.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


85. Zheng L, Wu PH, Mo YX, Xie CM, Ruan CM, Li L, Shen JX, Rong TH, Wang X, Zhang SY: [Mediastinal lymph node staging in non-small cell lung cancer: comparison between spiral computed tomographic findings and pathology]. Ai Zheng; 2006 Nov;25(11):1384-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal lymph node staging in non-small cell lung cancer: comparison between spiral computed tomographic findings and pathology].
  • BACKGROUND & OBJECTIVE: Mediastinal lymph node staging in non-small cell lung cancer (NSCLC) is important to choose standard treatment plan and estimating prognosis.
  • This study was to evaluate the clinical value of spiral CT in staging mediastinal lymph node in NSCLC through comparing spiral CT findings with corresponding pathology.
  • The spiral CT findings and corresponding pathologic findings in staging mediastinal lymph node were compared.
  • The sensitivity, specificity, and accuracy of diagnosing mediastinal lymph node metastasis were calculated.
  • RESULTS: Compared with corresponding pathologic results, the overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of mediastinal lymph node staging with spiral CT were 58.9%, 70.0%, 60.5%, 68.6%, and 65.2%, respectively.
  • The accuracy and specificity of spiral CT was relatively low in staging 4R, 5, 6, 7 lymph node groups; the false negative and false positive rates were relatively high in staging 4R, 7 lymph node groups.
  • CONCLUSIONS: Spiral CT is a non-invasive clinical examination which may be used in staging mediastinal lymph node in NSCLC; however, there exists false negative and false positive rates.
  • It should be combined with other investigations, such as mediastinoscopy, to assess a more accurate mediastinal lymph node staging.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Lung Neoplasms / radiography. Lymph Nodes / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. False Negative Reactions. False Positive Reactions. Female. Humans. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Neoplasm Staging / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094906.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


86. Lu XY, Zhang SL, Lu YM, Xiu XX, Sun XW: [The significance of K-Cl cotransport1 expression in cervical cancer tissues]. Zhonghua Yi Xue Za Zhi; 2007 May 8;87(17):1156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The significance of K-Cl cotransport1 expression in cervical cancer tissues].
  • OBJECTIVE: To investigate the expression of K-Cl cotransport 1(KCC1) in cervical cancer tissues and to investigate its role in the onset and progression of cervical cancer.
  • METHODS: Specimens of uterus were obtained from 60 patients aged 45.89 (25 approximately 73), 40 with cervical cancer, 10 with cervical intraepithelial neoplasia (CIN), and 10 with chronic cervicitis.
  • RESULTS: The mRNA expression and protein expression of KCC1 were both significantly higher in the cervical cancer tissue than those in the CIN and chronic cervicitis tissues (all P < 0.05).
  • The levels of KCC1 in the lowly differentiated cancer tissues (at grades G(2) and G(3)) were significantly higher than those in the highly differentiated cancer tissues (at grade G(1), P < 0.05).
  • Western blotting revealed that the protein expression level of KCC1 was significantly higher in the cervical cancer tissues than in the CIN and chronic cervicitis tissues (both P < 0.05) and the protein expression levels of KCC1 in the cancer tissues at G" 2 and G(3) grades were significantly higher than that in the cancer tissues at grade G(1) (both P < 0.05).
  • There were no significant differences in mRNA and protein expression between the early and terminal cervical cancer tissues.
  • There were no significant differences in the mRNA and protein expression of KCC1 between the cervical cancer cases with or without lymph node metastasis.
  • Immunofluorescence assay showed that KCC1 was located in the cellular membrane in all patients and the KCC1 expression level there was significantly higher in the cervical cancer tissues than in the tissues of CIN and chronic cervicitis.
  • CONCLUSION: The expression of KCC1 is up-regulated in cervical cancer and it may play an important role in the onset and progression of cervical cancer.
  • [MeSH-minor] Blotting, Western. Cervical Intraepithelial Neoplasia / genetics. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Female. Fluorescent Antibody Technique. Humans. Microscopy, Fluorescence. Neoplasm Staging. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction


87. Lu X, Hu C, Ji Q, Shen C, Feng Y: Squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: the impact of radiotherapy. Tumori; 2009 Mar-Apr;95(2):185-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: the impact of radiotherapy.
  • AIMS AND BACKGROUND: Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site constitute about 5% of the total head and neck cancer, cases.
  • The aim of the present study was to analyze the prognosis in a series of patients and, in particular, the impact of different radiotherapy techniques on the prognosis.
  • METHODS AND STUDY DESIGN: Data from 60 patients with cervical lymph node metastases of squamous cell carcinoma from an unknown primary site were reviewed.
  • The primary tumor emerged in 23.3% of patients treated with ipsilateral and bilateral neck irradiation and in 12.5% of patients irradiated by extensive field (P = 0.469).
  • CONCLUSIONS: Patients with cervical lymph node metastases of squamous cell carcinoma from an unknown primary site have clinical features and a prognosis similar to those of other head and neck malignancies.
  • Extensive irradiation results in a lower trend of emergence of the primary tumor than when patients are treated with ipsilateral and bilateral irradiation, but there is no significant difference in overall survival.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiotherapy. Lymph Nodes / pathology. Lymph Nodes / radiation effects. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neck. Neck Dissection. Neoplasm Staging. Prognosis. Radiotherapy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579864.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Apple SK, Moatamed NA, Finck RH, Sullivan PS: Accurate classification of sentinel lymph node metastases in patients with lobular breast carcinoma. Breast; 2010 Oct;19(5):360-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accurate classification of sentinel lymph node metastases in patients with lobular breast carcinoma.
  • Among pathologists there is low reproducibility in classifying small volume metastases in sentinel lymph node particularly in cases of invasive lobular carcinoma.
  • We postulate that strict adherence to American Joint Commission on Cancer (AJCC) 2003 criteria may result in inaccurate staging of lobular carcinoma patients.
  • We reviewed cases of metastatic lobular carcinoma in sentinel lymph node biopsies between 1998 and 2008.
  • All sentinel lymph nodes were reassessed using strict adherence to AJCC 2003 criteria.
  • Subsequent axillary lymph node dissection and clinical follow-up were reviewed.
  • Fifty-one patients met our inclusion criteria and were originally classified by the primary pathologist as follows: 10 isolated tumor cells, 8 micrometastases, 27 macrometastases, and 6 'positive' cases without further classification.
  • Cases were re-classified using strict adherence to AJCC 2003 criteria as follows: 21 isolated tumor cells, 2 micrometastases, and 28 macrometastases.
  • Twelve isolated tumor cells cases underwent full axillary dissection, and 3 (25%) had additional macrometastases.
  • Diffuse single cells or small clusters should not be interpreted as isolated tumor cells in invasive lobular carcinoma sentinel lymph nodes.
  • The criteria for assessing small volume metastases in the sentinel lymph node of patients with invasive lobular carcinoma need to be more clearly defined.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Neoplasm Staging / standards. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Observer Variation. Practice Guidelines as Topic. Reproducibility of Results. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20347308.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


89. Sleeman JP, Thiele W: Tumor metastasis and the lymphatic vasculature. Int J Cancer; 2009 Dec 15;125(12):2747-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor metastasis and the lymphatic vasculature.
  • Tumor-associated lymphatic vessels act as a conduit by which disseminating tumor cells access regional lymph nodes and form metastases there.
  • Lymph node metastasis is of major prognostic significance for many types of cancer, although lymph node metastases are themselves rarely life-threatening.
  • These observations focus our attention on understanding how tumor cells interact with the lymphatic vasculature, and why this interaction is so significant for prognosis.
  • Tumors interact with the lymphatic vasculature in a number of ways, including vessel co-option, chemotactic migration and invasion into lymphatic vessels and induction of lymphangiogenesis.
  • Tumor-induced lymphangiogenesis both locally and in regional lymph nodes has been correlatively and functionally associated with metastasis formation and poor prognosis.
  • Blockade of tumor-induced lymphangiogenesis in preclinical models inhibits metastasis formation in lymph nodes and often also in other organs, suggesting that blocking the lymphatic route of dissemination might suppress metastasis formation not only in lymph nodes but also in other organs.
  • However, randomized clinical trials that have investigated the efficacy of therapeutic removal of lymph nodes have concluded that lymph node metastases act only as indicators that primary tumors have developed metastatic potential, and do not govern the further spread of metastatic cells.
  • To reconcile these apparently paradoxical observations we suggest a model in which tumor-induced lymphangiogenesis and lymph node metastasis formation act as indicators that tumors are producing factors that can act systemically to promote metastasis formation in distant organs.
  • [MeSH-minor] Animals. Humans. Lymphatic Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 UICC.
  • (PMID = 19569051.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 165
  •  go-up   go-down


90. Chang YL, Wu CT, Lee YC: Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg; 2007 Sep;134(3):630-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: According to our previous study, the concurrent detection of p53 and epidermal growth factor receptor mutations significantly improves the clonality assessment and impact management of patients with multiple primary lung cancer.
  • The relationships among the location of tumors, number of tumors, tumor size, tumor histology, vascular invasion, regional lymph node metastasis, extranodal extension, type of surgery, mortality, and survival were analyzed.
  • Notably, lymph node metastasis, extranodal extension, vascular invasion, tumors with adenosquamous carcinoma or different histology, and poor survival were observed.
  • Multivariate analysis showed that only the occurrence of lymph node metastasis remained a statistically significant prognostic factor.
  • The 5-year survivals were 15.5% [corrected] and 52.5% [corrected] for patients with and without lymph node metastasis, respectively (P < .001).
  • CONCLUSION: An aggressive surgical approach is safe and justified in patients with synchronous multiple primary lung cancers and node-negative diseases.
  • The status of this particular form of non-small cell lung cancers might be considered in the conventional TNM staging system for more accurate prediction of patient prognosis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Cardiovasc Surg. 2008 Aug;136(2):542
  • (PMID = 17723810.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Bozdogan N, Bozdogan O, Pak I, Atasoy P: FAS, FAS ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study. Int J Dermatol; 2010 Jul;49(7):761-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FAS, FAS ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study.
  • BACKGROUND: FAS and its ligand, FASL, have important roles in the neoplasia-immunity relationship.
  • In this study, we aimed to demonstrate the distribution of FAS/FASL in melanotic lesions and to investigate the correlation between tumor infiltrating lymphocytes and macrophages.
  • METHODS: Ten intra-dermal nevi, 12 primary malignant melanoma, and eight skin and 15 lymph node metastases were included in this study.
  • Tumor infiltrating lymphocyte status and macrophage number demonstrated by CD68 immunostain were also evaluated in primary melanoma and skin metastases.
  • There were significant differences in FASL between nevus and primary melanoma, nevus and skin metastasis, and nevus and lymph node metastasis.
  • There were strong positive correlations between FAS expression and intra-neoplastic macrophage score and between FASL and density of lymphocyte infiltration in skin metastases.
  • The correlation between FAS status and macrophage number and between FASL status and lymphocyte number in skin metastasis but not in primary lesions might point to diverse FAS/FASL interaction between neoplastic cells and macrophages in the different microenvironments.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618494.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD95; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / FAS protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein
  •  go-up   go-down


92. Enomoto K, Uchino S, Ito A, Watanabe S, Shibuya H, Enomoto Y, Noguchi S: The surgical strategy and the molecular analysis of patients with parathyroid cancer. World J Surg; 2010 Nov;34(11):2604-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The surgical strategy and the molecular analysis of patients with parathyroid cancer.
  • BACKGROUND: Parathyroid cancer is a rare endocrine tumor, and the prognostic factors for this cancer remain unclear.
  • The standard therapy is en bloc resection of the primary tumor at the time of the initial operation.
  • However, the clinical significance of prophylactic neck dissection (PND) in the management of parathyroid cancer has not yet been established.
  • In this study, we investigated its clinical significance in patients with parathyroid cancer and the association of gene mutations with tumor progression.
  • METHODS: A total of 12 patients with parathyroid cancer were treated and have been followed at Noguchi Thyroid Clinic and Hospital Foundation since 1977.
  • In all, 11 patients were treated with the initial surgery for the cancer, and 1 patient underwent surgery for a metastatic lung lesion.
  • RESULTS: En bloc resections of thyroid tissue were performed in 10 patients, and 1 patient underwent only parathyroidectomy with limited resection of the thyroid gland.
  • PND was performed in eight patients, and no lymph node metastases were found in the histological specimens.
  • Six of the eight patients had no evidence of the disease, and two had recurring disease (neck lymph node and lung in one patient and local, lung, and brain in another).
  • PND was not performed in three patients, two of whom had no evidence of the disease and one with recurrence at the site of a regional lymph node.
  • Among the 12 patients with parathyroid cancer, 1 had a germ-line mutation of the HRPT2 at exon 7, codon 234, CGA (Arg) to TGA (Stop), and 1 patient had a tumor-specific mutation at exon 1, nucleotide 34-37 delAACA.
  • CONCLUSIONS: PND for patients with parathyroid cancer resulted in no evidence of lymph node metastasis and does not improve the prognosis.
  • HRPT2 gene mutation may be associated with tumor recurrence.
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Male. Middle Aged. Mutation. Neck Dissection. Parathyroidectomy. Prognosis. Proto-Oncogene Proteins / genetics. Tumor Suppressor Proteins / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Mar 1;100(5):900-5 [14983483.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):724-31 [1413841.001]
  • [Cites] Medicine (Baltimore). 1992 Jul;71(4):197-205 [1518393.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Dec;77(6):1485-9 [7903311.001]
  • [Cites] Cancer. 1970 Nov;26(5):1061-4 [5476787.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):676-80 [12434154.001]
  • [Cites] World J Surg. 1984 Aug;8(4):547-51 [6485352.001]
  • [Cites] Cancer. 1970 Nov;26(5):1053-60 [5476786.001]
  • [Cites] Cancer. 1960 May-Jun;13:502-6 [14446529.001]
  • [Cites] World J Surg. 1984 Jun;8(3):392-400 [6464494.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Jul;65(1):9-16 [16817812.001]
  • [Cites] Curr Treat Options Oncol. 2001 Aug;2(4):347-54 [12057115.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] Surgery. 1984 Dec;96(6):1132-7 [6505966.001]
  • [Cites] J Paediatr Child Health. 2002 Jun;38(3):314-7 [12047705.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):388-97 [7053835.001]
  • [Cites] Ann Surg. 1969 Apr;169(4):631-40 [4886854.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5553-7 [11034102.001]
  • [Cites] World J Surg. 1998 Dec;22(12):1225-30 [9841748.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):53-8 [18084346.001]
  • [Cites] Surg Oncol. 1999 Nov;8(3):155-65 [11113666.001]
  • [Cites] World J Surg. 2009 Nov;33(11):2343-54 [19350316.001]
  • [Cites] Mayo Clin Proc. 2002 Aug;77(8):866-9 [12173721.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):657-63 [12960210.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):535-42 [6353951.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1177-83 [9215690.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2378-84 [14635072.001]
  • [Cites] Semin Surg Oncol. 1997 Mar-Apr;13(2):142-54 [9088070.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5583-91 [15531515.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] Arch Intern Med. 1984 Feb;144(2):399-400 [6696578.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Sep;67(3):370-6 [17555500.001]
  • (PMID = 20480190.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


93. Zhou Q, Suzuki K, Anami Y, Oh S, Takamochi K: Clinicopathologic features in resected subcentimeter lung cancer--status of lymph node metastases. Interact Cardiovasc Thorac Surg; 2010 Jan;10(1):53-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features in resected subcentimeter lung cancer--status of lymph node metastases.
  • Whether systematic lymph node (LN) dissection should be done or not on subcentimeter lung cancers still remains controversial.
  • From June 2000 to December 2008, the records of all patients who underwent resection of primary non-small cell lung cancer (NSCLC) 1 cm or less in diameter were reviewed.
  • LN metastases and lymphatic vessel invasion (LVI) were studied between different subgroups to determine the predictors of metastases.
  • There were 6 (15%) cases with nodal metastases.
  • Tumor differentiation, visceral pleural involvement, preoperative serum carcinoembryonic antigen (CEA), ground-glass opacity content on CT and blood vessel invasion (BVI) were significant predictors for both LN metastases and LVI.
  • Systematic LN dissection is recommended for subcentimeter patients with good risk, however, if the patient is female, or with normal CEA, or with ground-glass opacity, or with Noguchi A or B type, surgeons might omit the procedure.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Carcinoembryonic Antigen / blood. Cell Differentiation. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Patient Selection. Retrospective Studies. Risk Assessment. Risk Factors. Sex Factors. Tomography, Spiral Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833638.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


94. Kim HS, Kim JW, Cho JY, Chung HH, Park NH, Song YS, Kim SH, Kang SB: The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI. Eur J Surg Oncol; 2009 Aug;35(8):870-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
  • BACKGROUND: We sought to identify the role of serum CA-125 levels in early-stage epithelial ovarian cancer (EOC) on preoperative CT and MRI.
  • Clinical stage I (n=59) was defined as tumor limited to the ovaries with or without ascites, whereas clinical stage II (n=42) was defined as tumor within the pelvis with or without ascites.
  • The primary endpoint was to investigate the efficacy of serum CA-125 levels for the prediction of advanced-stage disease, and secondary endpoints were to evaluate the accuracy of preoperative CT and MRI, and to examine the role of serum CA-125 levels as a prognostic factor for survival.
  • RESULTS: The results of preoperative CT and MRI were concordant with no peritoneal implants outside the pelvis in 50/101 (50%) and no lymph node metastasis in 71/101 (70%) patients.
  • The receiver operating characteristic curves showed that best cut-off values of serum CA-125 levels were 320 U/ml (71% sensitivity, 84% specificity) and 510 U/ml (67% sensitivity, 80% specificity) for the prediction of peritoneal implants outside the pelvis and lymph node metastasis.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179039.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen
  •  go-up   go-down


95. Inoue M, Okumura M, Minami M, Shiono H, Sawabata N, Utsumi T, Ohno Y, Sawa Y: Cardiopulmonary co-morbidity: a critical negative prognostic predictor for pulmonary resection following preoperative chemotherapy and/or radiation therapy in lung cancer patients. Gen Thorac Cardiovasc Surg; 2007 Aug;55(8):315-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiopulmonary co-morbidity: a critical negative prognostic predictor for pulmonary resection following preoperative chemotherapy and/or radiation therapy in lung cancer patients.
  • OBJECTIVE: Preoperative therapy is an optional strategy for locally advanced lung cancer, although the indication for pulmonary resection is often marginal, when considering the survival benefit and perioperative risks.
  • When analyzing only those who died from lung cancer, the group without cardiopulmonary comorbidity showed a tendency for longer survival than those in the co-morbidity group (P = 0.092).
  • The 5-year survival rate for patients without lymph node metastasis was 52%, whereas it was 14% for those with residual node involvement (P = 0.002).
  • Lymph node metastasis and cardiopulmonary co-morbidity were shown to be independent poor prognostic predictors by multivariate analysis.
  • CONCLUSION: In addition to nodal status, preoperative cardiopulmonary co-morbidity should be noted when considering the operative indications following preoperative therapy for lung cancer patients.


96. Wang J, Miao LJ, Wu YM, Wu YJ, Wang XC: [Expression of AKT2, cyclin D1, and MMP-9 and their correlations to clinicopathologic features of non-small cell lung cancer]. Ai Zheng; 2006 Jan;25(1):69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of AKT2, cyclin D1, and MMP-9 and their correlations to clinicopathologic features of non-small cell lung cancer].
  • Abnormal expression and activation of AKT2 is observed in many kinds of tumor tissues.
  • This study was designed to investigate the expression of AKT2, Cyclin D1, and matrix metalloproteinase-9 (MMP-9) in human non-small cell lung cancer (NSCLC) tissue and their correlations to clinicopathologic features of NSCLC.
  • The expression of AKT2 wasn't correlated to age, sex, histologic subtype and differentiation, and TNM stage of NSCLC patients (P>0.05), but was correlated to lymph node metastasis (P<0.05).
  • The expression of Cyclin D1 and MMP-9 was correlated to lymph node metastasis and differentiation of squamous cell carcinoma (P<0.05); the expression of MMP-9 was correlated to TNM stage.
  • CONCLUSIONS: AKT2, Cyclin D1, and MMP-9 is related to development of lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Cyclin D1 / metabolism. Lung Neoplasms / metabolism. Matrix Metalloproteinase 9 / metabolism. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Differentiation. Female. Gene Expression Regulation, Neoplastic. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging


97. Straver ME, Aukema TS, Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, Vogel WV, Peeters MJ: Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging; 2010 Jun;37(6):1069-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
  • PURPOSE: The aim of this study was to assess the accuracy of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT to visualize lymph node metastases before the start of neoadjuvant chemotherapy and to determine how often the visualization is sufficiently prominent to allow monitoring of the axillary response.
  • METHODS: Thirty-eight patients with invasive breast cancer of >3 cm and/or lymph node metastasis underwent FDG PET/CT before neoadjuvant chemotherapy.
  • The results of the FDG PET/CT were compared with those from ultrasonography with fine-needle aspiration (FNA) cytology or sentinel node biopsy.
  • Patients suitable for response monitoring of the axilla were defined as having either a maximum standardized uptake value (SUV(max)) >or= 2.5 or a tumour to background ratio >or=5 in the most intense lymph node.
  • No difference existed between the SUV(max) of the primary tumour and that from the related most intense lymph node metastasis.
  • Moreover, the mean tumour to background ratio was 90% higher in the lymph nodes compared to the primary tumour (p = 0.006).
  • Ninety-three per cent of the patients had sufficient uptake in the lymph nodes to qualify for subsequent response monitoring of the axilla.
  • A considerable distinction in metabolic activity was observed between the different subtypes of breast cancer.
  • The mean SUV(max) in lymph node metastases of oestrogen receptor (ER)-positive, triple-negative and human epidermal growth factor receptor 2 (HER2)-positive tumours was 6.6, 11.6 and 6.6, respectively.
  • CONCLUSION: The high accuracy in visualizing lymph node metastases and the sufficiently high SUV(max) and tumour to background ratio at baseline suggest that it is feasible to monitor the axillary response with FDG PET/CT, especially in triple-negative tumours.
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Humans. Lymphatic Metastasis. Middle Aged. Sensitivity and Specificity


98. He CY, Jin YL, Yang DM, Liu HG: [Clinicopathologic study of sinonasal inflammatory myofibroblastic tumor]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of sinonasal inflammatory myofibroblastic tumor].
  • One patient had lymph node metastasis and 3 patients died of the disease.
  • Histologically, the tumor cells were arranged in interlacing fascicles and sometimes haphazard in fashion.
  • They were spindly in shape, cytoplasm eosinophilic with mild nuclear atypia and a low mitotic activity.
  • In 3 of the recurrent cases, the tumor cells displayed increased nuclear atypia and mitotic activity (average about 5 to 6 per 10 high-power fields), accompanied by patchy necrosis, less inflammatory cell infiltration and focal sarcomatous changes.
  • Immunohistochemical study showed that the tumor cells were diffusely positive for vimentin.
  • The Ki-67 proliferation index increased with tumor recurrences.
  • The tumor is prone to local invasion and recurrences, with subsequent progression to frank malignancy and distant metastasis, resulting in high mortality and poor prognosis.
  • [MeSH-minor] Actins / metabolism. Adult. Calcium-Binding Proteins / metabolism. Diagnosis, Differential. Female. Fibrosarcoma / pathology. Humans. Ki-67 Antigen / metabolism. Lymphatic Metastasis. Male. Microfilament Proteins / metabolism. Middle Aged. Neoplasm Recurrence, Local. Neurofibromatoses / pathology. Vimentin / metabolism

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450762.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Calcium-Binding Proteins; 0 / Ki-67 Antigen; 0 / Microfilament Proteins; 0 / Vimentin; 0 / calponin
  •  go-up   go-down


99. Liu WK, Jiang XY, Zhang ZX: Expression of PSCA, PIWIL1 and TBX2 and its correlation with HPV16 infection in formalin-fixed, paraffin-embedded cervical squamous cell carcinoma specimens. Arch Virol; 2010 May;155(5):657-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Up-regulated expression of TBX2 had a positive association with lymph node metastasis (P = 0.014).
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Membrane Glycoproteins / analysis. Neoplasm Proteins / analysis. Papillomavirus E7 Proteins / analysis. Proteins / analysis. T-Box Domain Proteins / analysis. Uterine Cervical Neoplasms / etiology
  • [MeSH-minor] Antigens, Neoplasm. Argonaute Proteins. Female. Formaldehyde. GPI-Linked Proteins. Humans. Immunohistochemistry. Paraffin Embedding

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20229117.001).
  • [ISSN] 1432-8798
  • [Journal-full-title] Archives of virology
  • [ISO-abbreviation] Arch. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Argonaute Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PIWIL1 protein, human; 0 / PSCA protein, human; 0 / Papillomavirus E7 Proteins; 0 / Proteins; 0 / T-Box Domain Protein 2; 0 / T-Box Domain Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


100. Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, Takano Y: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch; 2008 May;452(5):525-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was found that MT carcinomas exhibited large size, deep invasion, frequent local invasion, and lymph node metastasis in comparison with IT and DT carcinomas (p < 0.05).
  • The invasive depth, venous invasion, lymph node, peritoneal or liver metastasis, and Lauren's classification were independent prognostic factors for gastric carcinomas (p < 0.05).
  • [MeSH-major] Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Malignant / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Cell Adhesion. Cell Proliferation. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Protein Array Analysis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):571-84 [7479380.001]
  • [Cites] Oncology. 1995 Jul-Aug;52(4):334-9 [7539903.001]
  • [Cites] Gen Diagn Pathol. 1997 Jul;143(1):39-48 [9269907.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):114-33; discussion 133 [15895459.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):363-71 [16489634.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3B):2353-60 [16821616.001]
  • [Cites] Gastric Cancer. 2006;9(3):177-84 [16952035.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1A):259-65 [17352241.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] J Pathol. 2000 Mar;190(4):437-43 [10699992.001]
  • [Cites] Br J Surg. 2000 May;87(5):618-26 [10792320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):75-8 [11205493.001]
  • [Cites] Chem Rev. 2001 Aug;101(8):2527-40 [11749387.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] IARC Sci Publ. 2004;(157):327-49 [15055305.001]
  • [Cites] J Pathol. 2004 Jun;203(2):681-7 [15141383.001]
  • [Cites] Gastric Cancer. 2004;7(2):61-77 [15224192.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1989 Jan;11(1):37-40 [2550197.001]
  • [Cites] Cancer. 1990 May 1;65(9):2086-90 [2372774.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):103-11 [7903667.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • (PMID = 18266006.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2329735
  •  go-up   go-down






Advertisement